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INTRODUCTION 
Hypertension is an evolving global burden to health. 
Essential hypertension  (EH) is an intricate disorder with various genetic and 
environmental influences leading to its occurrence. Research on animal models 
have revealed that polygenic hypertension is based on complex genetic 
architecture and potent genomic regulations. The contribution of genetic factors 
to hypertension have also been revealed from the considerable clustering in 
families and the constancy among twins. Thus by identifiying the genes 
vulnerable to cause essential hypertens in it’ll be useful in defining its 
pathophysiology and in recognising the high risk populations and to decide on 
specific therapy regime.  
Arterial hypertension is one of the key risks in development of 
cardiovascular diseases. Despite few recognized uncommon types of 
secondary hypertension, essential hypertension seems to be the most frequent 
diagnosis. The heritable basis of this disorder has been well noted in numerous 
familial studies. The amount of input by the genetic factors to variations in 
blood pressure is roughly around 30%, yet it remains complex and presently not 
fully understood. This study is framed to focus on the genetic backdrop 
of essential hypertension with particular attention to its association with leptin 
gene .  
Epidemiological data propose that 65–75% of possibility for hypertension 
is ascribed to increased weight
1,2
. Obesity probably via enhanced SNS activity, 
remains a source for amplified cardiovascular morbidity and mortality. 
Recently, hormones secreted by adipose tissue are gaining significance in 
research studies linking obesity and hypertension. Studies have shown that 
adipose tissue has become an important regulatory site that produces numerous 
immune-modulators and biologically active molecules
3,4
 . Among these diverse 
substances, leptin seems to have evolved as an imperative hormone with 
significant pleiotropic activities on multiple organs 
5,6
. 
Leptin , a  16-kDa-peptide is chiefly produced by the adipose tissue.  
Majority of its functions is via its action on hypothalamus. It  controls energy 
balance by drop in appetite and rise in temperature. Thus it regulates appetite 
and energy outflow. Also growing research datas substantiate that leptin, via 
multiple mechanisms, possibly has a significant influence on the regulation of 
CVS and renal and sympathetic nervous system outflow. Though  the 
importance of endogenous leptin requires more elucidation, physiologically it 
seems to be involved in pressure and volume-regulation. Conversely, in 
pathological states like chronic hyperleptinemia as seen in obesity, perhaps it 
might lead to evolvement of hypertension and probably cause injury to 
cardiovascular and renal system. Leptin induced sympathetic activation must be 
the most likely cause for obesity linked hypertension. Even though obesity is 
commonly related with opposition to the appetite suppression and weight 
lowering effecs of leptin, there is conservation of its sympathetic activation and 
pressor effects. This discriminating effect associated with hyperleptinemia, 
could be a crucial cause for the cardiovascular manifestations in obesity.   
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
Review of Literature 
REVIEW OF LITERATURE 
HYPERTENSION:  
Hypertension can be classified into two major categories based on its 
etiology. They are primary or essential hypertension (EH) and secondary 
hypertension.(Figure:1) Secondary hypertension are rare forms of hypertension 
with well established causes. Essential hypertension is the most frequent type of 
hypertension. EH is postulated as a long standing increase in blood pressure 
with no known, distinct cause
7
. Essential hypertension contributes to significant 
morbidity and mortality. However frequent, it currently remains as a composite 
disorder with indefinable causes. Being a continuous variable,  BP is a 
quantitative trait.  Latest animal model data revealed a complex genetic 
structure of quantitative trait loci (QTLs) for blood pressure (BP). From various  
familial and epidemiological studies it is understood that hypertension occurs 
due to composite interaction among heritable and environmental factors.  
Intricate QTL–QTL connections and potent genomic control mechanisms are 
the basis of polygenic hypertension. Research works are needed further to offer 
likely genetic mechanisms to describe the basis of essential hypertension.  
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FIGURE:2 :  
 
JNC 7
TH
 REPORT- GUIDELINES FOR DIAGNOSIS OF 
HYPERTENSION 
 
TERMINOLOGY Systolic BP Diastolic BP 
Normal ≤ 120 ≤ 80 
PRE HYPERTENSION 120-129 80-84 
 130-139 85-89 
HYPERTENSION           ≥140 ≥90 
Stage 1 (Mild 
hypertension) 
140-159 90-99 
Stage 2 (Moderate 
hypertension) 
160-179 100-109 
Stage 3 (Severe 
hypertension) 
≥ 180 ≥ 110 
Isolated Systolic 
hypertension 
≥ 140 ≤ 90 
 
  
 Definition: 
 According to the recent guidelines from the American Joint National 
Committee on prevention, detection, evaluation and treatment of high blood 
pressure (JNC VII) 
7
 hypertension is defined as a systolic blood pressure ≥ 
140mm Hg and/or a diastolic blood pressure ≥ 90mm Hg. (Figure:2)   
The criteria for defining hypertension varies between many research 
groups. Thus  the level of BP beyond which anti-hypertensives will become 
beneficial than left untreated can be used to define HT. 
Guidelines & Classifications: 
Different organizations have generated disease-specific guidelines for 
various conditions and hyper tension is one among them. The JNC VII report is 
given in figure:2 
Aetiology of hypertension: 
There are two types:  
a. Primary or essential hypertension :  
 It is a multifaceted disease with obscure causes. The genetic and 
ecological factors contributing to its prevalence makes it a multifactorial 
disorder. Over 95% of patients with hypertension present with such a picture. 
1. Genetic predisposition – A family history of hypertension, heart disease, 
type2 diabetes mellitus 
2. Non –modifiable factors– Age 
3. Modifiable factors – Stress, high calorie diet, overweight, smoking, heavy 
drinking, sodium rich diet, lack of physical exercise. 
b. Secondary hypertension :  
 2 to 5%; has an underlying cause, usually involving the renal and the 
endocrine system 
Causes:  
a) Endocrine :  
                Adrenocortical hyperfunction –  
1. Cushings’ disease and syndrome 
2. Primary hyperaldosteronism 
3. Congenital adrenogenital syndrome (17α-hydroxylase and 
11α -hydroxylase defects) 
4. Myxedema 
5. Acromegaly 
6. Adrenal medullary involvement:   Pheochromocytoma 
b) Vascular :                    
           1.  Coarctation of aorta 
2. Stenosis of renal artery  
3. Renal infarction 
c) Renal : 
1. Intrinsic renal disease  
2. Polycystic kidney 
3. Chronic kidney diease 
d) Medications  : 
           1. OCPs  
2. Adrenergic drugs 
Epidemiology :   
24% of all coronary heart disease deaths and 57% of all stroke deaths are 
directly attributed to Hypertension in India
8
.  
Pathogenesis: 
The pathogenesis is multifactorial and highly intricate for essential 
hypertension. Several factors alter the pressure in the vasculature for adequate 
blood supply to various organs. They include humoral mediators, cardiac 
output, circulating volume, viscosity, blood vessel elasticity ,  vascular calibre, 
endothelial response,  and neural stimulation. Multiple factors have been 
proposed as possible pathogenesis of essential hypertension. They include 
Heredity:  
 Genetic factor has been understood to be involved in the genesis of 
hypertension. Most studies sustain the theory that the genetic basis is most 
likely multifactorial. It is more likely to have a complex association of multiple 
genes rather than a single gene to account for the heritability of this disorder. 
Both susceptibility genes and monogenic defects have been reported to be 
having one of their consequences an increased arterial pressure. Various 
epidemiological studies and familial studies imply the complex interplay among 
various factors such as genetic susceptibility, ecological lifestyle exposures like 
intake of sodium in food, surplus alcohol consumption and body weight
9
. Also 
it has been suggested from twin studies that inter-individual variation of BP is 
heritable 
10
. 
Epigenetic mechanisms:  
 Aberrant DNA methylation has been linked to many age related 
disorders including hypertension
11,12
 .  For example, the  epigenetic 
dysregulation of estrogen receptor β has been found to participate in 
development of essential hypertension 
13
 
Intra-uterine factors: 
Several data suggest a possibility that the blood pressure of an adult is 
established depending on the birth weight of a fetus.  It is a vicious cycle 
showing pregnant women with high normal or even greater blood pressure 
reproduces low birth weight babies. These babies  consequently develop high 
normal blood pressure and in due course they develop hypertension which may 
be due to the associated metabolic abnormalities such as IR, DM, lipid 
disorders, and abdominal obesity. This theory is named as “Barker hypothesis”. 
14
 
Environment: 
 A number of environmental factors including high sodium intake, excess 
weight gain, alcohol ingestion play an important role in elevation of blood 
pressure along with age. 
PATHOPHYSIOLOGY 
Cell membrane defect: 
Generalised cell membrane defect is one possible explanation. This 
hypothesis derives most of its information from the studies on circulating blood 
elements, which have documented the abnormalities in the sodium transport 
across the cell membrane. Several cells of the body, in particular, the vascular 
smooth muscle cells exhibit this defect. This causes an abnormal calcium 
accumulation in the vascular smooth muscle which in turn leads to increased 
vascular reactivity. 
Intravascular Volume 
The two main determinants of hypertension are raised cardiac output and 
increased peripheral vascular resistance
15
. Cardiac output is calculated by heart 
rate and stroke volume. The latter inturn depends on the force of contraction and 
the ventricular volume. Peripheral resistance depends on anatomic and 
functional alterations in of the blood vessels. 
Vascular volume is calculated by arterial pressure over the long term. 
Variations in total ECF volume is directly related to the blood volume. 
Extracellular fluid volume is calculated by sodium which is an extracellular ion. 
When the intake of sodium chloride exceeds the kidney’s capacity to excrete 
sodium, vascular volume expands and cardiac output increases. However, 
various vascular beds including brain and kidney have the capacity to self 
regulate blood flow, and the resistance within that bed must increase, if constant 
blood flow is to be maintained.  
Blood flow  = pressure across the vascular bed / vascular resistance
15
.  
Impaired sodium excretion :  
Impaired excretion of sodium leads to water retention which in turns 
increases the blood volume . Changes in the blood volume can alter the bp. In 
patients with CKD, blood volume correlates with the systolic blood pressure.  
This is mediated by the  abnormal vasoregulation and an increased systemic 
vascular resistance
16
. In individuals with an impaired capacity to excrete 
sodium, greater increases of arterial pressure are required to achieve natriuresis 
and sodium balance. 
Impaired pressure natriuresis:  
The effect of sodium on blood pressure is associated to the provision of 
chloride with sodium. High sodium chloride intake causes increase in arterial 
pressure, and sodium excretion through urine increases and sodium balance is 
maintained at the expense of an increase in arterial pressure. The mechanism is 
called  "pressure-natriuresis" phenomenon. In Chronic kidney disease there is  
impaired pressure natriuresis leading to  loss of ability to alter sodium handling 
based on small changes in bp. Hence the hypertensive response to Angiotensin-
II and aldosterone is diminished when the increased pressure is transmitted to 
the kidney
16
. 
Autonomic Nervous System 
Sympathetic nervous system stimulation can lead onto either constriction 
or dilatation of the arterioles. Hence the SNS plays a vital function in 
maintainence of bp in the physiological range. Blood pressure variations due to 
physical exercise, stress are also regulated by SNS. The mediators involved in 
blood pressure regulation are signals based on blood volume, pressor effects and 
chemoreceptors. Short term regulation of bp is via sympathetic  reflexes and the 
long-term regulation involves the combined effects of SNS, volume and 
hormone-related factors. Norepinephrine, dopamine, and epinephrine are the 
three endogenous catecholamines which play an important role in tonic and 
phasic cardiovascular regulation.  
Several reflexes modulate blood pressure. The arterial pressure increases 
the rate of firing of the baroreceptors in the aortic arch and carotid sinuses, and 
the effect is a decrease of sympathetic outflow, resulting in decreases of heart 
rate and arterial pressure. This is a primary method for quick buffering of sharp 
fluctuations of arterial pressure that may occur during behavioral or physiologic 
stress, postural changes, and changes in blood volume. Patients with autonomic 
neuropathy and impaired baroreflex function may have extremely labile blood 
pressures with difficult-to-control episodic blood pressure spikes. Medications  
interfering with the SNS act as potent antihypertensive agents, representing the 
main part played by SNS in the maintenance of increased arterial pressure.  
RAAS: 
The renin-angiotensin-aldosterone system is the most important pathway  
in the maintenance of blood pressure through the sodium-retaining properties of 
aldosterone and the vasoconstrictor properties of angiotensin II 
17
.  
Increased activity of the renin-angiotensin-aldosterone axis is not 
invariably associated with hypertension
18
. In response to a low-sodium chloride 
diet or to volume contraction, arterial pressure and volume homeostasis may be 
maintained by increased stimulation of the RAAS.  
Vascular Mechanisms 
Blood  pressure is mainly determined by the vascular radius and 
compliance of resistance arteries. Flow resistance varies inversely with the 
radius (r⁴), and consequently smaller the lumen size more is the resistance. The 
lumen diameter of small arteries and arterioles of hypertensive patients may 
reduce with structural, mechanical, or functional changes. In subjects with 
raised bp the arteries become stiffer, and those with arteriosclerosis exhibit 
mostly high SBP and wide pulse pressures as a result of reduced arterial 
compliance due to structural changes in the vascular wall. Vascular endothelial 
function also modulates vascular tone by releasing vasoactive substances
19-21
. 
The nitric oxide is a potent vasodilator  synthesized by the vascular 
endothelium. Endothelium-dependent vasodilation is impaired in hypertensive 
patient. 
Insulin resistance: 
The increased arterial pressure has been attributed to Insulin resistance 
and hyper insulinaemia. The possible mechanisms that have been postulated are 
as follows
22
. 
a. Insulin has mitogenic action, which increases vascular smooth 
muscle hypertrophy. 
b. It causes retention of renal sodium and increased sympathetic 
activity, thereby increased  arterial pressure. 
c. Ion transport across the cell membrane is increased by Insulin, 
increasing the cytosolic calcium levels of insulin-sensitive renal or 
vascular tissues. 
Recently studies have demonstrated that high blood pressure is associated 
with high plasma leptin levels. An association between leptin and hypertension 
has been established clearly  from data of available animal studies, whereas 
results of human studies are less consistent. There are several possible 
mechanisms, which include 
a. One possible explanation is through sympathetic activation. Leptin 
administered intravenously and intracerebroventricularly in rodents has 
been found to increase the sympathetic outflow to kidneys, skeletal 
muscle vasculature and the neural traffic to the adrenal
23,24
 
b. It induces endothelin-1, which is a potent vasoconstrictor and mitogen
25
 
c. It promotes angiogenesis, which contributes to the modulation of 
endothelial cell proliferation in atherosclerosis
26
. 
d. It increases sodium and water excretion via a direct tubular action. But 
during leptin resistance it produces anti-natriuresis leading to 
hypertension
27
. 
Pathologic Consequences of hypertension : 
All clinical manifestations of atherosclerosis have hypertension as a 
possible etiological role. CAD, heart failure, retinopathy, kidney disorders, 
peripheral arterial disease (PAD) and stroke have hypertension as an 
independent predisposing factor. 
Heart 
The most frequent cause of death in hypertensives is due to cardiac 
involvement 
28
. Cardiac disease due to hypertension is the consequence of 
functional and structural adjustments resulting in diastolic dysfunction, LVH, 
heart failure due to congestion, alterations in the flow of blood, CAD , 
microangiopathy and arrhythmias.  
Vigorous control of  hypertension results in reversal of LVH and 
reduction in the possibility of development of CVD 
29,30
. In hypertensive 
patients, diastolic dysfunctions are frequent and remain as the premature 
outcome of hypertension. They vary from asymptomatic cardiac involvement to 
evident cardiac failure. In cardiac  failure due to diastolic dysfunction the 
ejection fraction is conserved as it results from systolic function.  
 
CNS 
Brain infarction and hemorrhage encompass hypertension as an important 
risk factor
31-33
. Stroke is also due to infarction and hemorrhage, either 
intracerebral hemorrhage or subarachnoid hemorrhage, thus linked to 
hypertension
34
. The rise in bp, predominantly the SBP in elderly increases 
progressively the incidence of stroke. The occurrence of stroke convincingly 
decreases with treatment of hypertension. Hypertension is linked with impaired 
cognition in old age people. Autoregulation of cerebral circulation
35,36
 fails, 
resulting in vasodilation and hyperperfusion ultimately leading to 
encephalopathy In malignant hypertension patients.  
Kidney 
Primary kidney disorder is the most frequent source of secondary 
hypertension. On the other hand, renal injury and ESRD are caused by 
hypertension. The increased risk linked with high blood pressure is graded, 
continuous, and present throughout the entire distribution of blood pressure 
above optimal
37-43
. The preglomerular arterioles are primarily affected  by the 
hypertension-related vascular lesions in the kidney 
44
, leading to  ischemia of 
the glomeruli and postglomerular structures. There is hyperperfusion in the 
glomerular capillaries leading to local injury and finally progressing to 
glomerulosclerosis
45
, ultimately there is resultant ischemia and gradual atrophy 
of the renal tubules.  
Peripheral Arteries 
Blood vessels contribute to the pathogenesis of hypertension , and as a 
result become a target organ for atherosclerotic disease. Hypertensive patients 
with arterio occlusive diseases of the lower limbs have greater chance of 
acquiring CVD at a later stage. Several studies suggest that an ankle-brachial 
index < 0.80 is associated with elevated blood pressure, particularly systolic 
blood pressure. Patients with hypertension are three times more prone to 
peripheral vascular disease as apparent by intermittent claudication. In larger 
vessels like the aorta, it progresses to aneurysm. 
Retinopathy  
Hypertensive retinopathy is caused by the vascular changes in the eye 
induced by hypertension
46
. The increase in bp causes a series of 
pathophysiological changes in the retinal circulation
47
. Keith, Wagener and 
Barker have classified these vascular changes into four grades. Malignant 
hypertension, the most severe form, is clinically defined as elevated bp 
combined with one or more of the following: 
1. Bilateral retinal flame-shaped haemorrhages 
2. Cotton wool spots 
3. Hard exudates  
4. Papilloedema. 
Diagnosis: 
The key to diagnosis of hypertension is the precise measurement of the 
blood pressure.  The preferable mode of recording blood pressure is by using a 
mercury manometer and taking average of three reading taken two minutes 
apart. Supine and sitting positions blood pressure measurements should be 
recorded, auscultating with the bell of the stethoscope. A wider cuff is preferred 
as even the size of the cuff may affect the blood pressure measurement. The 
subject should relax calmly for minimum five minutes prior to the recording of 
BP. Palpation of all peripheral pulses should be performed. 
Laboratory studies: 
The following routine laboratory investigations should be carried out in 
all cases of hypertension to make out the probability of target organ injury and 
to present a prior data to monitor the side effects of the treatment.   
* Urinalysis 
* Hematocrit 
* Serum potassium 
* Plasma glucose 
* Calcium 
* Serum creatinine 
* Electrocardiogram (ECG) 
* Chest radiography 
* Fasting plasma cholesterol and triglyceride levels for 
hyperlipidemia 
* Uric acid 
* Fasting plasma cholesterol and triglyceride levels for 
hyperlipidemia 
* Echocardiography in selected cases to monitor the cardiac status 
and to identify LVH 
When  a secondary cause is suspected or when the bp is not controllable, 
extensive investigations have to be carried out. 
Treatment: 
Lifestyle modifications – JNC VII recommend the following to lower 
blood pressure and decrease the risk of cardiovascular disease
48-51
. 
 Weight reduction52-54.  
 Limiting alcohol intake and smoking55,56. 
 Increased physical activity57. 
 Sodium intake reduction to less than 6 gms58,59. 
 DASH – dietary approaches to stop hypertension with adequate  dietary 
potassium, calcium & magnesium
59
. 
 Reduction of intake of dietary cholesterol and saturated fats.  
The JNC VII report
60
 recommends the following Initial therapy:- 
* Pre-hypertension (SBP – 120-139 mm Hg, DBP –  80-89  mm Hg): 
 anti-hypertensive drug is not indicated 
* Stage I (SBP –  140-159 mm Hg, DBP –  90-99 mm Hg): Thiazide 
diuretics are recommended. beta blocker, ACE inhibitor, CCBs or a 
combination of these may be used. 
* Stage II (SBP –  160 mm Hg, DBP – 100 mm Hg): Two drug 
combination (Thiazide diuretic and ACE inhibitor / beta blocker) is 
recommended. 
Prevention: 
Prevention, early detection and ample treatment forms the broad strategy 
for reduction in morbidity and mortality from hypertension. 
 Even a minimum decline in BP imparts considerable improvement in 
health. There is a considerable drop off in the occurrence of stroke (35%) &  
CAD (16%)
61
 by a fall in SBP by 10-12 mmHg and DBP by 5 -6 mm Hg. 
Prevention includes  
 Control of weight  
 Increase in physical activity 
 Moderate salt intake  
 Increased intake of K+ 
 Reduced ingestion of alcohol  
 Regular diet comprising adequate quantity of the following 
 - fruits 
 -vegetables 
 - low fat meat 
 - fish  
 -dairy products 
 
LEPTIN: 
  
FIGURE – 3 
 
 
 
 
 
 
Discovery: 
Leptin is an adipocyte derived hormone
62
. It was discovered by Jeffrey 
M. Friedman & co - Rockfeller University in the year 1994 
63
. It was named so 
from the greek word leptos- meaning thin. The gene coding for leptin is Ob 
gene. It is  located on chromosome 7q31.3 in humans
64,65
. 
Structure: 
          The ob gene produces a 167  aminoacids containing protein. (Figure:3) Its 
signal peptide sequence at the amino terminal contains 21 aminoacids. This 
secretory signal sequence results in the transport of leptin into microsomes. It is 
subsequently  cleaved off resulting in circulating leptin with 146 aminoacids
63
.  
Leptin is a 16 kDa peptide. It is a globular protein with a tertiary structure 
similar to hemopoietic cytokines such as interleukin and granulocyte 
macrophage colony stimulating factor
66
. 
Sources : 
The major source of leptin is white adipose tissue. It is also synthesised 
by brown adipose tissue and other extra adipocyte tissues such as brain, 
pituitary, placenta (syncytiotrophoblasts), ovaries, mammary epithelial cells
67
, 
skeletal muscle, bone marrow
68
, gastric chief cells,  lower part of fundic glands, 
P/D1 cells in the stomach and liver
69,70
. Its secretion is constitutive. There is no 
storage form for leptin
71
. 
Functions : 
Leptin circulates in proportion to the adipose tissue present in human 
body . (Figure:4)  Initially soon  after its discovery leptin was well known for its 
satiety action. This was accompolished via its action over hypothalamus 
mediating appetite suppression, energy expenditure, acceleration of metabolic 
rate and thermogenesis
72,73
 thereby controlling the body weight and regulating 
the accumulation of fat. (Figure:5)   Recent studies suggest that leptin has a 
wide range of functions involving various systems like the renal,  
   
FIGURE -  4 
 
 
 
  
 FIGURE 5. Role of leptin in regulation of 
adipose tissue mass leptin is secreted by adipocytes and 
circulates in the blood in concentrations proportional to fat mass 
content. interaction of leptin with its receptor in the 
hypothalamus inhibits food intake and increases energy 
expenditure through stimulation of sympathetic nerve activity. 
this leads to a reduction in adipose tissue 
mass. 
 
 
 
 
 
 
  
 
cardiaovascular and sympathetic nervous system 
5,6,74-77
.  Its  
physiological functions have extended from anti-obesity to variety of roles like 
formation of new blood cells and blood vessels, regulation of sympathetic tone 
and blood pressure maintenance,  reproduction, bone mass regulation, 
enhancing insulin sensitivity and immunity
78
. (Figure:6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 FIGURE – 6 
 
 
 
 
 
 
 
FIGURE – 7 
 
 
 
 
Leptin Gene-LEP:  
Leptin is a product of gene designated OB (Obese) or LEP(leptin). Gene 
location:  
OB/LEP gene is located in Chromosome 6 in mice and Chr.7q.31.3 in 
humans
64
. 
Gene structure:  
This gene has 3 exons separated by 2 introns in both rodents and 
humans
64
. The coding sequences of the gene is contained in exon 2 & 3 
separated by an intron, approximately 2 kb. (Figure:7) 
LEP encodes a 4.5 kilobase mRNA
63
. 
Gene expression:  
The mRNA of the OB gene is highly expressed in adipocytes
79
. It has 
been found that the OB mRNA expression is not detected in human pre-
adipocytes. It occurs following differentiation of 373L1 and 373F, 422A cells 
from fibroblasts to mature adipocytes 
80,81
. The major factor determining the 
amount of ob mRNA expression is the size of the adipocyte. Larger the cell size 
more is its expression. 
Leptin Receptors-LR:  
They are the member of the cytokine receptor super family- class I. There 
are six forms of LR produced by variations in the splicing process
82-86
. 
The leptin receptor (LR) is coded by LEPR gene or ObR gene
86
. In mice 
this gene is present on chromosome 4 and  in humans its location is on 
chromosome 1p 
87
. It has also been designated as  CD295  (cluster of 
differentiation 295).  
LR Forms :                                 
Till date six  isoforms of LR  have been discovered. They are Ob-Ra–Ob-
Rf, or LepRa-LepRf. Out of them ObRb is the longest form. It has the complete 
intracellular signaling capability
86
. It is the only form that can exert its function 
through the Jak-Stat and MAPK  pathways
88
. 
LR Structure: 
LRa single-transmembrane-domain receptor of the cytokine 
receptor family. All the isoforms have an extracellular domain. This is the only 
portion of the receptors that is required for ligand binding
63,89,90
 Structural 
analysis  and functional studies of the receptor reveal that it prevails regularly as 
a dimer pair. A single leptin molecule binds to one  LR in a reversible manner. 
Leptin OB-Rb receptor is found in hypothalamus. It is identical to that in 
choroids plexus except that the intracellular domain has additional 269 amino 
acids. The extra cellular domain contains Trp-Ser-X-Ser-Trp motifs and the 
intracellular domain has docking sites for janus kinases (JAK), a family of 
tyrosine kinases involved in intracellular cytokine signaling  and a signal 
transducer and activator of transcription (STAT) motif. OB-Rc and OB-Rd are 
speculated that they transport leptin through the BBB(Blood brain barrier). OB-
Ra which is a soluble receptor functions as a transport protein contributing to 
binding and activation of circulating leptin
91,92
. 
Localization: 
The LEPR gene is expressed  significantly in the lung and adipocytes, 
moderately by kidneys , relatively less in heart, spleen, liver, brain and 
muscle
93
. Various   tissues at the periphery express the short variant (LRa). 
ObRb- the long variant is expressed almost ubiquitously including the renal, 
cardiac and adrenal system 
93
  with maximum expression in hypothalamus.  
Transport of leptin :                 
Leptin is considered to cross the BBB via the choroid plexus which has 
increased expression of LRa
94
. Thus this short variant is suggested to be one of 
the major transport route of leptin into the brain. This route is a single way 
transport system which gets saturated
95
. 
Mode of action: 
It has been recognised that the action of  leptin has more peripheral 
actions than thought earlier. Other than its endocrine effect linking the fat tissue  
with CNS, it also has autocrine and paracrine actions
24
.  
Secretion : 
Leptin is predominantly secreted by fat cells into blood. Leptin exists in 
both free form (physiologically active) and complex form with binding 
proteins
96,97
. As the adiposity raises there is a relatively equal increase in 
circulating free leptin levels
96
.  Its secretion is pulsatile
98
 with diurnal-nocturnal 
variation, the highest levels observed during the night
98,99
.  Its concentration is 
assayed by immuno-precipitation or radioimmunoassay
100-102
.  
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Mechanism of action:  
Most of the biological functions of leptin like appetite suppression, heat 
production and activation of the sympathetic nervous system are performed via 
stimulating the long isoform LRb
84,103
. This leads to  activation of various 
intracellular signaling pathways like the  JAK2/STAT3, MAPK, PI3K and 
AMPK pathways. (Figure:8) 
On activation of LRb , one of the pathway JAK2 is stimulated (Janus 
kinase 2) 
84,103
. This leads to phosphorylation of tyrosine residues present on the 
longer LR which in turn induces signal transduction and activator of 
transcription-3 (STAT-3) proteins
83,104-107
. Phosphorylated STAT-3 proteins 
dimerize. They then shift to the nucleus and promote transcription. (Figure:9) In 
addition, downstream of JAK, LR activation also stimulates 
phosphotidylinositol 3-kinase (PI3K) and Ras-mitogen activated protein kinase 
(MAPK) signaling pathways
3785,86,93,106-108
. Negative regulators of leptin 
signaling  are SOCS-3 (suppressors of cytokine signaling protein) and PTP1b 
(protein tyrosine phosphatase 1b)
82-86
. 
In the CNS, activation of Jak2 via LRb leads to phosphorylation of 3 
tyrosine moieties. This in turn results in 3 major signal routes: 
1) Phosphorylation of Tyrosine-1138 attracts inactive STAT3 towards LRb-
Jak2 complex, leading to addition of phosphate group and activation of 
STAT3. Active STAT3 undergoes a  shift into the nucleus leading on to 
transcription of genes. 
2) Addition of phosphate group to IRS2 (insulin receptor substrate 2) results 
in stimulation of phosphatidylinositol 3-kinase (PI3K)  
3) Addition of phosphate group to Tyrosine-985 attracts tyr phosphatase 
Shp2 leading to  stimulation of MAPK pathway. 
Stimulation of a variety of intracellular signaling routes via LR at various 
CNS areas suggest that there is a divergent regulation of appetite, energy 
expenditure ,BP in obesity. 
Physiological roles of leptin : 
Leptin seems to play a variety of functions ranging from regulation of 
energy utilization, as a signal of metabolic status,  growth inducer in different 
types of tissues, permissive factor for puberty, regulation of metabolism during 
pregnancy, interaction  with various hormones and modulators of energy like 
insulin, glucocorticoids, glucagon, growth hormone,IGFs.  
Satiety and energy balance: 
Leptin is an indicator of energy balance and provides satiety signal. On 
the contrary, according to some authors foremost function of leptin is to serve as 
the “starvation indicator” to maintain sufficient lipid reserves for withstanding 
the states of deficient energy  rather than being a “satiety indicator” to control 
excess fat deposition when there is lot of energy
109,110.
 
In brain leptin acts on its receptors in the hypothalamus and either 
activates or inhibits various pathways.   
Leptin enhances the production of α-MSH, which causes suppression of 
appetite. This leads to control on appetite on a long-term manner while the other 
appetite suppressants like cholecystokinin (CCK)  has rapid inhibition and 
PYY3-36 has slower suppression of appetite. Leptin counteracts the feeding 
stimulants like neuropeptide Y and anandamide. Thus the absence or defect of 
leptin or its receptor results in excessive appetite  and finally to increased 
adiposity. Various research works have revealed that leptin is more sensitive to 
starvation than to overfeeding
111
. Its level gets decreased when on a fast or on a 
very-low-calorie diet (VLCD)
112-114
. Thus by regulating appetite leptin controls 
the energy balance
115,116
. Melatonin regulates leptin levels during night. Role of 
melatonin is controversial. One study suggests a raised level of melatonin will 
lead on to decreased concentrations of leptin
117
. Another study reveals that there 
is a decrease in appetite during sleep as melatonin enhances leptin 
concentrations
118
.  
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Mechanism of action of leptin in CNS:  
LRs are expressed in various hypothalamic nuclei like the arcuate 
nucleus,PVN, VMH AND DMH
119
. (Figure:10) 
Arcuate  nucleus is thought to be the prime target for the action of 
circulating leptin into a neuronal response
120
. On injecting leptin focally on this 
site it suppresses intake of food. After destruction of the arcuate nucleus, if 
leptin is administered directly into brain there is no effect on appetite or  
  
 
 
FIGURE 11. interaction of leptin with Vneuropeptide y 
(npy)/agouti-related protein (agrp)- and proopiomelanocortin 
(pomc)/cocaineand amphetamine-regulated transcript (cart)-
containing neurones in the 
hypothalamic arcuate nucleus leptin stimulates the pomc/cart 
catabolic pathway and inhibits the npy/agrp 
anabolic pathway, leading to an increase in sympathetic nerve 
activity (sna) and reduced food intake. α-msh, α-
melanocytestimulating hormone; mc-3r, melanocortin 
receptor 3; mc-4r, melanocortin receptor 4; npy-r, neuropeptide y 
receptor. 
  
sympathetic nerve activity 
121
. Signals from arcuate nucleus are relayed 
onto PVN and lateral hypothalamus
119
. 
Leptin involves different neuronal circuits for its anorexigenic, metabolic 
and sympathetic actions. It triggers the catabolic pathway proopiomelanocortin 
(POMC)/cocaine-and amphetamine-regulated transcript (CART) neurons and 
inhibits the anabolic pathway represented by the neuropeptide Y (NPY)/agouti-
related protein (AgRP) neurons. Both these neurons relay onto PVN and lateral 
hypothalamic area
122
. POMC/CART neurons also project to the adrenergic  
preganglionic neurons present in the medulla and spinal cord
122
. (Figure:11) . 
The various pathways involved in mediating leptin’s action are as follows:    
1. Melanocortin system: 
One of the pathways for leptin’s action on CNS is the melanocortin 
system 
119
. Leptin acts over LRs on the POMC neurons present in arcuate 
nucleus to produce melanocortins (eg. alpha-melanocyte stimulating hormone 
or α-MSH) . (Figure:12) This in turn act on a variety of melanocortin receptors. 
There are 5 such receptors. MC-1R,  MC-2R, MC-3R, MC-4R, MC-5R MC-3 
and 4R are the predominant forms in CNS. 
MC-4R is important in regulating the energy status and any destruction to 
its  gene causes increased appetite and excess weight gain in mice
123
. Also when 
hypothalamic MC-4R receptors are  stimulated they increase the SNS activity to  
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BAT and kidney
124
. Inhibition of MC-4R inhibits the sympathoexcitatory 
properties of leptin over the renal system while BAT remains unaffected
124
. This 
selective inhibition suggests that control on sympathetic nerve activity by leptin 
is in a tissue specific way via multiple signalling routes.  
2. Neuropeptide Y :  
NPY which is produced from neurons of the arcuate nucleus acts on PVN 
and lateral hypothalamus. NPY increases food intake and enhances obesity
125
. 
These effects result from action on NPY-Y1 & NPY-Y5 receptors. Also  the 
NPY neurons produce a potent blocker of the melanocortin receptors 3&4 
named agouti related peptide (AgRP). This  AgRP  gets increased during fasting 
and during deficient leptin levels. This augments food intake and reduces the 
energy expense by antagonizing melanocortin receptors 
126
. Leptin blocks NPY 
gene transcription and translation and thereby reduces obesity
127
. 
Administration   of neuropeptide Y to animals via intracerebroventricular route 
decreases sympathetic activity to interscapular brown adipose tissue and 
kidney
128
. Thus, blockage of neuropeptide Y signalling route seems to be one of 
the key mechanisms of central action of leptin to regulate energy status. 
3. Corticotrophin Releasing Factor(CRF):  
In brown adipose tissue (BAT) the sympathetic activation by leptin seems 
to be carried out by CRF for the reason that this activation is blocked by an 
antagonist to CRF receptor 
129
. This adds to the possibility that leptin controls 
SNS at different sites in a tissue specific way through a variety of signalling 
pathways.   
Sexual dimorphism: 
In human-beings, leptin displays a difference in their concentrations in 
both sexes . This sexual dimorphism is evident in both ob mRNA expression
130
 
and in the correlation between concentrations of leptin and body fat mass
131,132
.  
Leptin concentrations are greater in women when compared to men
131,133
. 
Though with similar  BMI, females tend to have greater adipose tissue mass 
than males,  this fact doesn’t contribute to the sexual dimorphism of leptin 
levels. It seems  to arise independent of adiposity
131,133
. 
A couple of reasons could be put-forth  for this dimorphism. 
1. One reason could be that, females have a greater subcutaneous to omental 
fat ratio 
134
. This higher ratio is significantly associated with leptin 
expression in women
130
. Thus reflecting that, these gender variations are 
due to the local distribution of fat mass and  local leptin expression.  
2. Another reason could be due to influence of sex hormones over leptin 
131,133
. It is proposed that such gender dimorphism in the production of 
leptin are due to the stimulatory effects of estrogen or due to inhibitory 
effects of androgens
80
 
135-137
, while such an association among the above 
hormones was inconsistent in another study
138
. 
Leptin and BMI: 
Leptin levels and its expression increases as the amount of triglyceride 
stores  in adipose tissue increases
100,139
. Serum leptin correlates specifically with 
the body mass index and percentage of fat  in humans
96,97
. Recent studies show 
that inspite of no changes in the adiposity, there is a peak rise in serum leptin  
levels due to increased caloric intake 
140,141
 but there is no increase acutely in the 
postprandial state
99
. Whereas leptin expression and its concentration decreases 
intensely during starvation
142,143
. Therefore, alterations in adipose tissue mass  
and sudden alterations in energy homeostasis seem to contribute to  regulation 
of concentrations of leptin. It is found that the adipocyte differentiation is in 
turn controlled by CCAAT/enhancer-binding protein a (C/EBPa)
144,145
. This 
protein is a transcription factor which positively regulates the promoter region 
of LEP. 
 
Hormonal influence on leptin levels: 
Insulin increases the production of leptin and its secretion from human 
adipocytes 
146,147
. Following a high calorie intake, there is increase in insulin  
 FIGURE - 13 
 
 
 
 
 
 
  
which stimulates rise in leptin levels in a dose-dependent manner
148
. This 
is potentiated by high cortisol levels
146
.  
Hyperinsulinaemia over a long term, increases leptin production and the 
serum leptin concentrations in humans but however this effect is not seen in 
acute rise in insulin levels 
149-151
. Serum leptin levels were increased in 
hyperinsulinaemic lean individuals with insulin resistance
152
 while subjects with 
NIDDM and PCOS, insulin resistant conditions did not have an increased leptin 
levels
153,154
.  However, it is unclear whether this association with higher serum 
leptin levels is independent of obesity. 
High levels of glucocorticoids increase leptin expression
155
. Higher serum 
leptin levels are seen in Cushing's syndrome
156
 independent of body adiposity. 
Positive regulators of leptin are mainly cytokines which include  TNF
154
 and 
interleukin1 and the negative regulators are beta3-adrenergic agonists and cyclic 
AMP (cAMP)
157
. Decreased serum leptin levels are associated with cigarette 
smoking possibly due to adrenergic activation 
158
. However, hyperthyroidism 
another hyperadrenergic state did not have any effect on leptin levels
159,160
. 
(Figure:13) 
Selective leptin resistance :  
Serum leptin levels are significantly raised in obese persons when 
compared to thin subjects
100
. This seems to be due to the resistance to metabolic  
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effects of leptin as hyperleptinemia cannot regulate the fat mass in obese 
persons. In animal studies  it has been demonstrated that in obesity, there is 
resistance to the suppression of appetite by leptin but not to its action on SNS 
161,162
. Also the neutral  action of leptin in maintaining the normal vascular tone 
is impaired in chronic hyperleptinemia found in obesity. Increased leptin levels 
may enhance the smooth muscle cell proliferation in the blood vessels
163
 . This 
concept was termed as “selective leptin resistance”.  
Leptin and insulin: 
Leptin  has been found to enhance the sensitivity of insulin & 
simultaneously lowering its production. Sequentially, insulin enhances secretion 
of leptin, thereby setting up an ‘adipo-insular axis’. (Figure:14) 
Leptin increases insulin sensitivity at its physiological levels. However in 
case of hyperleptinemia as in leptin resistance it is shown to cause insulin 
resistance. (Figure:15) 
Insulin resistance and hyperinsulinemia per se are linked to 
hypertension
164-166
. This is due elevated adrenergic activity
136,137
  and renal 
sodium reabsorption. Thus the most probable cause for the link between obesity 
and hypertension is insulin resistance and the consequent hyperinsulinemia
167
. 
Elevated leptin levels also seem to be responsible for increased blood pressure  
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by adrenergic
168,169
 or renal
170
 mechanisms and has been highly suggested 
as another possible link for hypertension. 
Leptin Resistance: 
Possible factors involving leptin resistance
84,171-174
 (Figure:16) 
1. Saturation of the leptin transport carriers into the central nervous 
system. 
2. Changes in leptin signalling routes within the hypothalamus eg. 
phosphorylation of  serine residues in IRS-1(insulin receptor 
substrate-1). 
3. Activation of inhibitors to leptin signaling pathways like SOCS3. 
4.  Defects in the leptin receptor but their mutations are rare in 
humans. 
Differential actions of leptin: 
It is suggested that there is differential regulation of energy status and 
SNS activity
175
.  
 
Leptin has differential  actions over sympathetic system controlling the 
metabolic and cardiovascular functons. This  is revealed by the finding that the 
stimulation of baroreceptors specifically blocks renal sympathoactivation by 
leptin but doesnot alter its sympathoactivation in the BAT 
176
. It is a found that 
leptin’s sympathoactivation in the kidneys play a major role in its pressor 
effects and is regulated by the baroreflex.  Leptin’s sympathoexcitation in the 
brown adipose tissue contributes to its metabolic regulation. These two effects 
of leptin involve different neuronal pathways.  
 
Melanocortin- 4 receptor antagonists inhibit renal sympathoactivation  by 
leptin but doesn’t affect leptin’s BAT sympathoactivation124. BAT 
sympathoexcitation by leptin is blocked by a CRF receptor antagonist
129
. The 
varying predilection to hypertension in obese subjects could be due to 
differential resistance to leptin’s action in controlling metabolic status and SNS 
activation. Thus this could be the possible reason for elevated leptin levels in 
obese hypertensives to be much more greater than those with obesity,normal 
blood pressure
177
. Serum leptin concentration and bp were related in graded 
positive manner  independent of BMI, abdominal adiposity and insulin 
resistance
178
. 
Research studies on humans suggest that there is a significant relation 
between increased leptin levels and increased bp in both sexes  even after 
adjusting for the influence of body mass index and insulin resistance 
179,180
. 
Higher plasma leptin levels have a positive association with increased bp after 
controlling the influence of age, sex, race/ethnicity,BMI,smoking,DM and 
cholesterol levels
181
. There is possibility of strong link between leptin and the 
RAS over the maintenance of blood pressure. This interaction was postulated by 
recent studies where there was a fall in leptin concentrations by administering  
ACE inhibitors and AT receptor blockers
182,183
. Melanocortin system may also 
play a potential part in leptin's maintenance of blood pressure
124
. It is suggested 
that the MC4R might be involved in the SNS activity of leptin
184
. (Figure:17) 
Mutation in MC4R gene showed poor association of raised bp in obesity
185
. 
Leptin and heart: 
Leptin might be involved in cardiovascular functions. Chronic  
hyperleptinemia may indirectly lead to cardiac disorders through sympathetic 
overactivation, pressor effects, increased platelet aggregation, impaired 
fibrinolysis and proangiogenic actions
75,174,186,187
 and inflammatory response 
through C-reactive protein stimulation(CRP)
188,189
. 
Leptin and blood vessels: 
 Leptin promotes angiogenesis by increasing vascular endothelial growth 
factor (VEGF) levels. 
Role of leptin as an Inflammatory marker 
The leptin has a significant function in imparting inflammatory response. 
Other inflammatory inducers like sleepdisorders, stress, caloric limitation and 
adiposity seem to acutely affect leptin levels also  
190-192
. Leptin specifically 
responds to adipose-derived inflammatory cytokines. Leptin resembles IL-6 
both by structure and function
66,191,193
. Plasma leptin affects the HPA axis, 
indicating  its part in stress response
194
. Increased leptin levels correlate with 
increased WBC counts in both men and women
195
. Unlike IL-6, leptin is not 
affected by exercise. Leptin stimulates angiogenesis, inflammation and 
mitogenesis
196
.  
Role of leptin in sodium handling: 
Leptin  seems to be a natriuretic hormone. It helps in excretion of sodium 
and water by functioning in the renal tubules. In chronic hyperleptinemia there 
is a predilection to an enhanced SNS activity which leads to an additional rise in 
bp and a blunted natriuretic effect with reduced clearance of sodium and water. 
The reasons for this blunted natriuretic effect are not fully identified. Suggested 
mechanisms are the down regulation of LR 
75,197
 ,post-receptor signalling 
alterations
75,84,106
, increased breakdown of NO by oxidative stress
198
 ,or over 
stimulation of the efferent RSNA causing antinatriuresis
199
. An important 
physiological role of leptin is to control salt and water balance. Also dietary 
sodium has a positive correlation with synthesis and secretion of leptin 
200
. It is 
found that under varied states of physiology, the response to leptin’s natriuretic 
effect and vascular tone changes. 
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Role of leptin in blood pressure regulation: 
Physiologically leptin is known to have both pressor and depressor 
effects. (Figure:18) The depressor effects are believed to be due to  natriuretic 
effect of leptin, stimulation of endothelial nitric oxide which has vasodilatory 
effect and indirectly by increasing the insulin sensitivity. The pressor effects are 
due to increased SNS activity and due to adverse shifting of pressure-natriuresis 
curve
201,202
. Although leptin has dual and opposite roles over blood pressure 
regulation, in order to maintain a normal vascular tone usually the pressor 
effects predominate the depressor effects in vivo. Thus when there increased 
levels of leptin as in leptin resistance, it results in increased activation of the 
renal sympathetic system coupled with decreased natriuresis
203
. (Figure:19) 
Thus hyperleptinemia is likely to produce hypertension
204
.  
Leptin activates the SNS directly either by peripheral or by central 
actions on hypothalamus
205
 . According to study reports on animal models, 
leptin is believed to activate the sympathetic nervous system to produce vaso-
active response
205
.  On the contrary, there were no changes in blood pressure 
when leptin was injected on a short term basis. This postulates the probability of 
simultaneous stimulation of counter-regulatory mechanisms like NO-dependent 
vasorelaxation, EDHF and natriuresis which are known to cause vasodilation 
206,207
. This vasodilatory action is impaired in obese animals
208
. In such obese 
animals leptin levels were highly elevated. This inturn leads to increase in blood 
pressure by increased sympathetic nervous activity, sodium retention, nitric 
oxide deficit, increase Na-K-ATPase in kidneys, and excess synthesis of 
endothelin which is a potent vasoconstrictor
208-210
. Also an increase in activation 
of SNS and thereby blood pressure are also brought about by an increase in 
CRF in brain
129
.  
In accordance to the above factors, leptin deficiency in homozygous 
individuals  were associated with obesity and also defective SNS activity  
leading to decreased blood pressure 
211
.  
Mechanism involving hypertension: 
Chronic increase in leptin can raise BP. This increase in BP is completely 
destroyed by α-&β-adrenergic inhibitors. Thus it is highly suggestive that leptin 
mediated rise in BP is by SNS activation
212,213
. Increase in leptin levels 
increases BP in a slow fashion stating that the rise of SNS activity is not 
sufficient to produce a striking vasoconstriction. Instead, the enhanced SNS 
activity amplifies BP through the deliberate renal mechanism. The effects of 
leptin on increased BP are greatly exacerbated only when accompanied by 
impaired NO synthesis
212,213
. 
Role of POMC in hypertension: 
CNS POMC-MC3/4R system not only regulates energy balance but also 
cause SNS activation and hypertension. Long term activation of this system 
causes these effects whereas its inhibition lowers BP. 
MC4R is predominant in PVN and NTS 
214
.  It is a G-protein-coupled 
receptor which acts by increasing activity of adenylate cyclase
215
. Individuals 
with deficiency of this receptor are less prone to hypertension inspite of marked 
obesity
185
 .  
POMC neurons are located in immediate contact with hypothalamus 
along with LR
215
. Leptin augments the production of POMC which on 
activation leads to synthesis of α-melanocyte-stimulating hormone (α-MSH)215.  
In an animal study, deletion of LR specifically in POMC neurons and 
then chronic infusions of leptin didn’t result in an increased bp but there was no 
effect on appetite. This highly suggests that the role of leptin in regulating blood 
pressure is through the stimulation of POMC-MC3/4R route 
216
.Also 
stimulation of RSNA
124
 and thereby increasing BP
217
 by leptin were completely 
abolished by pharmacological antagonism of MC3/4Rs. 
These effects on BP are carried out  predominantly by MC4R 
218
. 
However inhibition of MC4R did not lower the SNS activity of leptin in BAT 
indicating a different neuronal pathway involvement other than that involving 
the RSNA and BP
124
. 
Leptin gene and hypertension: 
From animal studies it has been observed that mutations of LEP(OB) 
leads to profound obesity. In humans, such mutations are extremely uncommon 
in LEP gene. However many studies show a significant association between 
single nucleotide polymorphisms, tandem repeat polymorphisms of leptin gene  
and hypertension. Duanduan Ma et al. observed six LEP SNPs to be 
significantly associated with hypertension. A tetranucleotide  (TTTC)n repeat 
polymorphism was identified in the 3’UTR of leptin gene(LEP-tet) by Shintani 
et al. Polymorphism with fewer tetranucleotide repeats (<160 bp) were found to 
be significantly associated with hypertension
219
. This association was not 
dependent on BMI and insulin resistance. Similar results were obtained in few 
other studies 
220,221
. Another similar  study was carried out in India which also 
revealed a strong association between this tetranucleotide repeat polymorphism 
and EH but was not independent of obesity
222
. Few other studies were in 
contrast to these results showing nil association between LEP-tet polymorphism 
and hypertension
223,224
. One another study on linkage analysis conducted in 
African-Americans  between LEP and HT showed no significance
225
. 
In another study,  LEP-tet polymorphism was also associated with pulse 
pressure and carotid intimal thickness
226
. Also few authors studied this 
polymorphism,to find out any association with diabetes
227
 and obstructive sleep 
apnea
228
 and found no association. 
  
 
Aim of the Study 
AIM OF THE STUDY 
On reviewing the physiological role of leptin and its association with 
essential hypertension and the possible association of leptin gene tetra-
nucleotide repeat polymorphism at the 3’UTR with essential hypertension , the 
study has been taken up with the keen interest to establish the following aims 
and objectives: 
1. To know the distribution of genotypes &  their frequencies among 
hypertensives and apparently healthy controls. 
2. To  know the frequencies of the alleles( Class I &Class II) among 
hypertensives and apparently healthy controls. 
3. To find an association between class I allele and its associated risk of 
essential hypertension. 
4. To estimate serum leptin levels in subjects with essential hypertension 
and apparently healthy controls. 
5. To know the relation between genotypes and serum leptin levels among 
hypertensives and apparently healthy controls. 
6. To know the relation between the genotypes and BMI among 
hypertensives and apparently healthy controls. 
7. To determine whether there is any significant association between the 
genotypes and essential hypertension independent of obesity. 
8. To determine if there is any correlation between serum leptin levels and 
lipid parameters. 
9. To estimate fasting serum insulin levels in subjects with essential 
hypertension and apparently healthy controls. 
10. To calculate HOMA-IR among hypertensives and apparently healthy 
controls and to assess any link between the genotypes, leptin levels and 
insulin resistance. 
 
  
  
 
Materials and Methods 
MATERIALS AND METHODS 
 A case-control study was carried out between April’11 – September’12. It 
was done in 2 groups, namely, cases with essential hypertension and controls 
who were apparently healthy. 
Cases group: 
 This group comprised of 100 subjects with essential hypertension who 
were attending the hypertensive clinic and the master health checkup-OPD at 
Rajiv Gandhi Government General Hospital, Chennai. 
Based on the following inclusion and exclusion criterias subjects of this 
group were selected. 
Inclusion criteria: 
  Patients with confirmed diagnosis of essential hypertension based on 
history and blood pressure measurement using sphygmomanometer. 
Exclusion criteria: 
 Patients of essential hypertension with associated diabetes mellitus 
 Clinical information or lab data indicative of secondary hypertension 
  Valvular heart disease, arrhythmias, renal disease, coronary artery 
disease, cerebrovascular disease,endocrine disorders 
 Significant medical disorders: 
a. Cardiovascular diseases 
b. Thyroid disorders 
c. Renal diseases 
d. Adrenal disorders 
e. Hepatic diseases 
f.  Neurological disorders 
g. GastroIntestinal disorders 
h. Recent infection, inflammation(past 1 month) 
i. Recent drug intake 
* Lipid lowering drugs, 
* Non-Steroidal Anti Inflammatory Drugs, 
* Hormone Replacement Therapy, 
* Immunosuppressives, 
* Cox -2 inhibitors, 
* Oral Contraceptive Pills, 
* Mineralocorticoids, 
* Bromocriptine, 
* MonoAmineOxidase inhibitors 
Control group: 
The group comprised of 100 apparently healthy subjects with no 
significant medical illness. They were selected from the patients attending the 
master health checkup-OPD at Rajiv Gandhi Government General Hospital, 
Chennai. 
Sample collection: 
5 ml of peripheral venous blood was collected after an overnight fasting 
of 8-12hrs from all the study subjects. Blood  was withdrawn under sterile 
conditions with disposable syringes from the cubital vein of the subjects. 2 ml 
of the blood was transferred to a potassium EDTA tubes and the remaining  3ml 
of blood into plain tubes. Plasma and serum were separated from the above 
tubes respectively.  
Serum separated from the plain tubes was centrifuged at 2500 revolutions 
per minute for 5 minutes, to get clear serum without any cells. 1mL of serum 
was transferred into 1.5mL eppendorf. This was stored at -20°C for measuring 
the concentrations of leptin and insulin. The remaining serum was used to 
measure urea and creatinine within 6 hours of blood collection by enzymatic 
methods using commercial kits. 
EDTA tube was centrifuged at 2000 rpm for twenty minutes to get the 
buffy coat for DNA extraction. The plasma samples were analysed for glucose 
estimation and lipid profile estimation on the same day within an hour of 
collection.  
DNA extraction was done on the same day and extracted DNA was stored 
at -20°C. 
Height (in cms) and Weight (in kgs) of the subjects were measured to 
calculate the body mass index. 
BUFFY COAT SEPARATION 
Buffy coat was separated by centrifugation of  EDTA tubes at 2000 
revolutions for 20 minutes. Buffy coat was transferred to 2mL eppendorf and 
was used for DNA extraction. Plasma separated was used for glucose and lipid 
profile estimation. 
BIOCHEMICAL MARKERS 
Plasma glucose, serum urea, creatinine, total cholesterol ( TC), 
triglyceride(TGL) high density lipoprotein cholesterol (HDL-c)concentrations  
were estimated enzymatically using kits & Chem-7 semi-autoanalyser at 
Centralized Biochemistry Laboratory at Rajiv Gandhi Government General 
Hospital, Chennai-3.Low density lipoprotein cholesterol (LDL-c) was 
calculated using Friedwald’s formula. 
DNA EXTRACTION BY MODIFIED HIGH SALT METHOD
229
 
RBC Lysis: 
 400µL of buffy coat in a 2mL eppendorf is mixed with 1.6mL of 0.17M 
ammonium chloride and mixed by inversion until red cells are lysed for 
about 10 minutes 
 The cells are centrifuged at 4000rpm for 10minutes. 
 The white cell pellet is washed with 800µL of 0.17M ammonium chloride 
solution. The procedure is repeated till a clear white cell pellet is obtained. 
WBC Lysis 
 To the pellet 500 µL of TKM I solution is added. It is centrifuged at 
10,000rpm for 10minutes. 
 
Nuclear Lysis 
 Discard the supernatant. To the pellet add 500 µL of TKM II solution. To 
that add 300 µL of 6M  Nacl and 50 µL of 10% SDS. 
 Mix well (vortex), Centrifuge at 10,000 rpm for 10 minutes. 
 Save the supernatant. Transfer it to 1.5mL eppendorf. 
DNA Precipitation 
 To the supernatant double the volume of 100% ethanol is added. 
 The sample is stored at -20◦C for 1 hour. 
 Then it is centrifuged at 10,000 rpm for 20minutes at 4◦C in a refrigerated 
centrifuge. 
 The supernatant is discarded. To this 500 µL of 70% ethanol is added. The 
pellet is mixed and centrifugation done at 10,000 rpm for 10minutes at 4°C. 
 Remaining supernatant is discarded & the pellet is air dried. 
Storage 
 To the pellet 30 µL of LTE buffer is added and the extracted DNA is stored 
at   -20◦C for future use.  
Identification 
 Extracted DNA was identified by 0.8% agarose gel electrophoresis with a 
constant voltage of 7V/ cm and comparison with a known molecular weight 
1kb DNA ladder. (Figure:20) 
Concentration of extracted DNA: 
 Concentration of extracted DNA was estimated using UV 
spectrophotometer at 260 nm.  The absorbance at 260nm was 0.0204.  
 Concentration was calculated using the formula : 
1 OD is equivalent to 50 µg/mL. 
Conc. of DNA = absorbance X 50 µg/mL X dilution factor 
            =  0.0204 X 50 X 100 
=  102 ng/µL 
 Purity of extracted DNA was assessed by 260nm/280nm ratio and it was 
found to be >1.7.  
 
 
FIGURE – 20 
 
 
 
POLYMERASE CHAIN REACTION 
A tetra-nucleotide repeat(TTTC)n  polymorphism in the 3’-UTR of LEP 
gene was identified by polymerase chain reaction. 
Primer sequences were human OB forward and human OB reverse 
 Forward primer – 5’-AGTTCAAATAGAGGTCCAAATCA-3’ 
 Reverse primer- 5’-TTCTGAGGTTGTGTCACTGGCA-3’ 
Reconstitution of the Primers: 
Primers are supplied in lyophilized form. Autoclaved distilled water is 
used to prepare 100 × concentrations i.e. 10times the molecular weight of 
primer is the volume of water required to prepare 100 × concentrations which is 
100µmolar solution. 
 From this stock solution 10 × concentration is prepared as the working 
solution for PCR. 
MASTER MIX: 
 Genei Red Dye master mix in the following composition was used. 
 Master Mix consists of a unique inert red dye in addition to basic 
components necessary for PCR. 
* Reaction buffer consist of Tris Hydrochloric acid- 10 mM at   pH8.3 
                  Potassium chloride - 50 mM 
* MgCl - 1.5 mM acts as catalyst. 
* dNTP’s were used in a concentration of 2.5mM each. 
* Taq polymerase in a concentration of 1.5 U. 
* Primers were used in a concentration of 5 pmol and DNA was used in a 
concentration of 200ng. 
* PCR was carried out in a reaction volume of 25 µL with the following 
components; 
  PCR master mix –  12.5 µL 
Forward primer –     0.8 µL 
Reverse primer –     0.8 µL 
DNA                 –    2 .0µL 
Distilled water –     8.9 µL 
Total                – 25 µL 
* Amplification was carried out in an Mc Genei thermal cycler with the 
following cycling conditions. 
Initial denaturation – 940 C -3min 
35 cycles of  
Denaturation – 940C – 30sec 
Annealing    -   54
0
C – 30sec 
Extension  -      72
0
C – 1min 
Final extension at 72
0
C - 10 min. 
* Amplified product – amplicons was identified by 2% agarose gel 
electrophoresis by comparison with a known 100bp DNA ladder. 
(Figure:21)  
 FIGURE – 21 
 
 
 
 
* Amplified products are grouped into two classes. PCR products < 160 bp 
were grouped as Class I allele and PCR products >220bp were grouped as 
Class II allele. These PCR products were identified by 2% agarose gel 
electrophoresis by comparison with a known 100bp DNA ladder. Thus, 
each DNA sample revealed one of three possible patterns after 
electrophoresis: bands <160bp(I/I genotype), bands <160 and >220 bp 
(I/II genotype), or bands >220bp (II/II genotype) (Figure .22) 
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AGAROSE GEL ELECTROPHORESIS 
* PCR product is run on agarose gel in a 100 mL agarose cast as follows: 
2g of agarose is weighed and dissolved in 100mL of TAE buffer with a 
pH of 8.0. 
* It is microwaved for 2 mins, cooled and 5 µL of ethidium bromide 
(10mg/mL) is added. It is poured into a cast and allowed to solidify for 30 
min before it is kept in the electrophoresis tank.  
* 12 µL of PCR product is loaded onto wells and 4 µL of 100bp DNA 
ladder is loaded onto single well as a marker. It is electrophoresed at 
8V/cm for 45min and visualized under UV illumination. 
The biochemical parameters undertaken for the study were determined 
using the following methodologies:  
Estimation of Fasting plasma glucose: 
Method: Glucose oxidase peroxidase (GOD/POD), Enzymatic method 
Principle: 
Glucose oxidase 
Glucose +   O2                                                   Gluconic acid  +  H2O2  
            Peroxidase 
H2O2 + Phenolic compound+4aminoantipyrine                      Pink  
          coloured complex+2H2O 
            The intensity of pink coloured compound is directly related to amount of 
glucose and the OD was measured at 505nm. 
Procedure: 
To 1 ml of working reagent, 10 µL of plasma was added and incubation 
done at 37°C-fifteen minutes and OD was read at 505nm. 
Reference range :  
Fasting plasma glucose - →  70 - 100 mg/dL 
Estimation of Blood Urea: 
Method : GLDH method, Enzymatic method 
Principle: 
 The test is performed as a kinetic assay in which the initial rate of the 
reaction is linear for a limited period of time. 
Urea + H2O               Urease                         2NH4 + CO2 
   GLDH 
NH4 + NADH + H 
+
 + 2-Oxoglutarate                    Glutamate + NAD
+ 
 
The initial rate of reduction in OD at 340 nm is directly related to the 
concentration of  urea. 
Procedure: 
 To 1 mL of working reagent 10 µL of sample or standard is added. 
Absorbance is measured after 30 sec (A1) and 90 sec (A2). 
Estimation : 
∆A Sample          X   50 (Concentration of standard) = mg/dL of urea  
∆A Standard   
 
Reference range: 
Normal blood urea = 15 to 40 mg/dL 
Estimation of Serum Creatinine: 
Method :   Modified Jaffe’s Method. 
Principle: 
Creatinine complexes with alkaline picrate to give an orange-yellow 
coloured creatinine picrate. The intensity of this colour is directly proportional 
to creatinine concentration and is detected at 520 nm by spectrophotometer. 
Procedure: 
To 500 mL of working reagent 50 µL of serum sample or standard is 
added and initial absorbance (A1) is measured at 20 sec and final absorbance 
(A2) is measured at 80 sec after mixing. 
Calculation:  
∆A = A2 – A2 
Creatinine  =    ∆A of Test                    
   (mg/dL)                                      X   Concentration of Standard (2 mg/dl)  
                         ∆A of Standard             
Normal range :     0.6-1.2 mg/dL 
LIPID PROFILE 
Estimation of Plasma Total Cholesterol 
Method: Cholesterol Esterase – Cholesterol Oxidase 
Kit used:  Autospan of Span Diagnostics Ltd. 
Principle : 
                           Cholesterol Esterase            
Cholesterol Ester + H2O                                       Cholesterol+ Fatty acids 
                              
 
       Cholesterol Oxidase 
Cholesterol + O2                                                  Cholestenone + H2O2 
 
                                         Peroxidase 
H2O2  + Phenol + 4- Aminoantipyrine                         Red quinine + 4H2O 
 Red quinine is directly related to the cholesterol level and the OD is read 
at 500nm. 
Reagents :  
Reagent 1 (Enzymes / Chromogen) 
 Cholesterol Esterase                                200U/L 
 Cholesterol Oxidase                                 250U/L 
 Peroxidase                                               1000 U/L 
 4- Aminoantipyrine                                0.5 mmol/L 
 
Reagent 1A (Buffer) 
 Pipes buffer, pH 6.90                             50mmol/L 
 Phenol                                                     25mmol/L 
 Sodium Cholate                                      0.5 mmol/L 
Standard (Cholesterol = 200mg/dL) 
 Cholesterol                                              2g/L 
Procedure : 
 To 1 mL of the reconstituted reagent, 10 µL of plasma is added and 
reading is taken after 5 mins of incubation at 37
o
 C. 
Reference Values : 
 Cholesterol :  150-260 mg /dL 
Estimation of Plasma Triglyceride 
Method : 
 Enzymatic Colorimetric method 
Kit Used : 
 Autopak of Bayer Diagnostics 
Principle : 
                                       Lipoprotein Lipase 
Triglyceride + H2O                                            Glycerol + Fatty acid 
                               Glycerol Kinase 
Glycerol + ATP                                         Glycerol -3- Phosphate + ADP                                                                                                           
                                   Glycerol -3- Phosphate Oxidase 
Glycerol -3- Phosphate                                         
     Dihydroxyacetonephosphate+H2O2 
                                                               Peroxidase 
2 H2O2 + 4 Aminoantipyrine + ADPS                     Red Quinone + H2O 
 
    The intensity of coloured complex formed during the reaction is directly 
proportional to the triglyceride concentration and is estimated at 546nm.  
Reagents : 
Reagent 1 (Enzymes / Chromogen ) : 
 Lipoprotein Lipase                           1100U/L 
 Glycerol Kinase                               800U/L 
 Glycerol -3- Phosphate Oxidase      5000 U/L 
 Peroxidase                                        350 U/L 
 4- Aminoantipyrine                         0.7 mmol/L 
 ATP                                                  0.3 mmol/L 
Reagent 1A (Buffer) : 
 Pipes buffer. pH 7.50                      50mmol/L 
 ADPS                                                1mmol/L 
 Magnesium salt                                15 mmol/L 
Standard (Triglycerides 200mg / dL) : 
         Glycerol (Trig.Equivalent)              2g/L 
Reagent Reconstitution: 
 Reagents were brought to room temperature. Contents of one bottle of 
reagent 1 were dissolved with one bottle of reagent 1A. It was mixed gently by 
swirling. 
Procedure : 
 To 1 mL of the reconstituted reagent 10 µL of plasma is added and read 
at 546nm after incubation at 37
o
C for 5mins. 
Reference Range : 
 Males            60- 165 mg/dL 
 Females         40- 140 mg/dL 
 
Estimation of HDL Cholesterol 
 Method :        Immunoinhibition 
 Kit used :        Erba XL System Packs 
Principle : 
 Chylomicrons, VLDL, and LDL fractions in plasma are separated from 
HDL by immunoinhibition. This is achieved by complexing lipoproteins 
(Chylomicrons, VLDL, and LDL) other than HDL with Anti human -lipo 
protein antibody present in the reagent 1. When reagent 2 is added these 
complexes inhibits the enzyme reactions. Cholesterol esterase and cholesterol 
oxidase in reagent 2 react only with HDL-C. Hydrogen peroxide combines with 
F-DAOS and 4-aminoantipyrine (4-AA) in the presence of peroxidase(POD) 
and this gives a blue coloured complex. The strength of the colour produced 
measured at 593 nm is directly related to the HDL-C. 
                                          Anti-LipoproteinB antibody 
LDL, VLDL & Chylomicrons                  antigen antibody  
              complex   
         CHE & CO 
HDL-C + H2O +O2               4-cholestenone + Fatty acid + H2O2 
                                         Peroxidase 
H2O2 + DAOS + 4AAP                              Blue colored complex + 2H2O 
 
 
Reagents : 
Reagent 1 : 
Goods buffer pH 7.0 30.0mmol/L 
4-AAP                              0.9mmol/L 
POD                                  2400U/L 
Ascorbate oxidase             2700U/L 
Antihuman  lipoprotein antibody  
Reagent 2 : 
Goods buffer, pH – 7.0      30.0mmol/L 
CHE          4000U/L 
CO 20000U/L 
F-DAOS 0.8mmol/L 
Calibrator : 
 HDL-C   56.5mg/dL 
Procedure : 
 Reagent 1 & 2 are mixed in the ratio of 3:1 or 1 bottle of reagent 1 is 
mixed with 1 bottle of reagent 2 and placed in the auto analyser with the 
following assay parameters: 
Assay type : 2 point 
Primary wavelength nm : 600, Secondary wavelength nm : 700 
R-1 volume : 270, R-2 volume : 90 
Reaction direction : increasing, Sample volume : 3 µL 
Calibration : straight 
Reference Values : 
Adult male : 35.3 – 79.5 mg /dL 
Adult female : 42.0 – 88.0 mg / dL 
VLDL and LDL Cholesterol 
These parameters were calculated using Friedwald’s formula given below: 
 LDL-C       = TC-(HDL-C+ VLDL-C) 
 VLDL-C     = TGL/5 
Estimation of Serum Leptin levels – ELISA method 
Samples:  
In the present study serum samples were stored at -20
o
c and analysed 
within 3 months. 
Human Leptin Assay by ELISA: 
Principle: 
          This enzyme immunoassay test is based on 2-step capture / sandwich 
ELISA. 2 very specific MABs are used: 
One leptin-specific  MAB is used 
Other  MAB is specific for a different epitope of leptin which is 
conjugated to biotin. 
The monoclonal antibody specific for leptin is immobilized onto the the 
microwell plate and another monoclonal antibody specific for a different 
epitope of leptin is conjugated to biotin. 
Step 1: Leptin present in the samples and standards is bound to the 
immobilized antibody and to the biotinylated antibody, thus forming a sandwich 
complex. Excess and unbound biotinylated antibody is removed by a washing 
step.  
Step 2: Streptavidin-HRP is added, which binds specifically to any bound 
biotinylated antibody. Again, unbound streptavidin-HRP is removed by a 
washing step. 
Step 3: The enzyme substrate TMB is added, forming a blue coloured 
product that is directly proportional to the amount of leptin present. 
Step 4: The enzymatic reaction is terminated by the addition of the 
stopping solution, converting the blue colour to a yellow colour.  
The absorbance is measured on a microtiter plate reader at 450nm. 
A set of standards is used to plot a standard curve from which the amount 
of leptin in patient samples and controls can be directly read. 
Reagents: 
Human leptin ELISA kit was procured from dbc-Diagnostics Biochem 
Canada Inc.. Each kit has 96 microtiter well plate and contains the following 
reagents. 
1. One 96 well (12*8) antileptin monoclonal antibody coated microwell 
plate- break apart wells. 
2. Monoclonal anti-leptin antibody conjugated to biotin in a protein-
based buffer with a non mercury preservative.  
3. Streptavidin- HRP Conjugate in a protein-based buffer with a non 
mercury preservative 0.4mL/vial. Preparation: Dilute 1:50 in assay 
buffer before use (eg. 40µL of concentrate in 2 mL of assay buffer. 
Preparation: dilute 1:50 in assay buffer before use (eg.40 µL of 
concentrate in 2 mL of assay buffer). If the whole plate is to be used 
dilute 240 µL of concentrate in 12 mL of assay buffer.  
4. Leptin calibrators-  
 Contents: Six vials containing leptin in a protein-based buffer with a non-
mercury preservative. Prepared by spiking buffer with a defined quantity of 
leptin. 
Calibrator Concentration Volume/vial 
Calibrator A 0 ng/mL 0.5 mL 
Calibrator B 1 ng/mL 0.5 mL 
Calibrator C 5 ng/mL 0.5 mL 
Calibrator D 10 ng/ mL 0.5 mL 
Calibrator E 20 ng/ mL 0.5 mL 
Calibrator F 50 NG/ mL 0.5 mL 
Calibrator G 100 ng/ mL 0.5 mL 
 
5. Controls 
 Contents: two vials containing leptin in a protein-based buffer with a non-
mercury preservative. Prepared by spiking buffer with defined quantities of 
leptin 
 
6. Wash buffer concentrate 
 Contents:  Buffer with a non-ionic detergent and non-mercury 
preservative. 
 
 Preparation: dilute 1:10 in distilled or deionized water before use. If the 
whole plate is to be used dilute 50 ml of the wash buffer concentrate in 450 ml 
of water. 
 
7. Assay buffer 
 Contents: A protein- based buffer with a non- mercury preservative. 
 
8. TMB Subtrate 
 Contents:  Tetramethylbenzidine and hydrogen peroxide in a non-DMF or 
DMSO containing buffer. 
 
9. Stopping solution 
 Contents: 1M sulfuric acid. 
Storage and stability:  All reagents were refrigerated at 2-8°C 
Assay procedure : 
 All reagents must reach room temperature before use.  
1. Prepare working solutions of the streptavidin-HRP conjugate and 
wash buffer. 
2. Pipette 20µL of each calibrator, control and serum sample into 
correspondingly labelled wells in duplicate. 
3. Pipette 80µL of the monoclonal anti-leptin-biotin conjugate into 
each well. 
4. Incubate on a plate shaker (approximately 200 rpm) for 1 hour at 
room temperature. 
5. Wash the wells 3 times with prepared wash buffer(300 µL/ well for 
each wash) and tap the plate firmly against absorbent paper to 
ensure that it is dry. 
6. Pipette 100 µL of prepared streptavidin-HRP conjugate into each 
well. 
7. Incubate on a plate shaker (approximately 200 rpm) for 30 minutes 
at room temperature. 
8. Wash the wells again in the same manner as step 5. 
9. Pipette 100µL of TMB substrate into each well at timed intervals. 
10. Incubate on a plate shaker for 10 -15 minutes at room temperature. 
11. Pipette 50µL of stopping solution into each well at the same timed 
intervals as in step 9. 
12. Read the plate on a microwell plate reader at 450nm within 20 
minutes after addition of the stopping solution. 
CALCULATIONS : 
1. Calculate the mean optical density of each calibrator. 
2. Draw a calibrator curve on semi-log paper with the mean optical densities 
on the y-axis and the calibrator concentrations on the x-axis. If 
immunoassay software is being used, a 4-parameter or 5-parameter curve 
is recommended. 
3. Calculate the mean optical density of each unknown sample. 
4. Read the values of the unknowns directly off the calibrator curve. 
5. If a sample reads more than 100 ng/mL then dilute it with assay buffer at 
a dilution of no more than 1:8. The result obtained should be multiplied 
by the dilution factor. 
 
Typical tabulated Data: 
Calibrator OD1 OD2 Mean OD Value 
(ng/mL) 
A 0.073 0.070 0.072 0 
B 0.102 0.100 0.101 1 
C 0.290 0.293 0.292 5 
D 0.620 0.630 0.625 10 
E 1.140 1.086 1.113 20 
F 1.947 1.919 1.933 50 
G 2.518 2.514 2.516 100 
Unknown 0.275 0.273 0.274 422 
 
EXPECTED NORMAL VALUES 
 As for all clinical assays each laboratory should collect data and 
establish their own range of expected normal values. 
GROUP MEAN (ng/ mL) RANGE (ng/ mL) 
Lean Women 7.4 3.7-11.1 
Lean Men 3.8 2.0-5.6 
 
 Leptin values are approximately 2.5 times higher in women than men per 
unit BMI. 
Human insulin assay by ELISA:  
The calbiotech Insulin ELISA Kit was used for the quantitative 
measurement of Insulin in human serum. 
PRINCIPLE OF THE TEST 
The insulin ELISA is a solid phase two-site enzyme immunoassay. It is 
based on the direct sandwich technique in which two monoclonal antibodies are 
directed against separate antigenic determinants on the insulin molecule. During 
incubation insulin in the sample reacts with the enzyme (HRP)-conjugated anti-
insulin antibody and anti-insulin antibody bound to micro-titration well. A 
simple washing step removes unbound enzyme labeled antibody. The bound 
HRP complex is detected by reaction with TMB substrate. The reaction is 
stopped by adding acid to give a colorimetric endpoint that is read using ELISA 
reader. 
MATERIALS PROVIDED       
1. Microwell coated with Insulin MAb 
2. Insulin Standard 1-6 
3. Insulin Enzyme Conjugate 
4. Assay Diluent 
5. TMB Substrate 
6. Stop Sloution 
7. 20X Wash concentrate 
Storage and Stability 
All reagents were stored at 2-8° C. 
SPECIMEN COLLECTION HANDLING 
1. Blood  specimens were collected and the serum was separated 
immediately. 
2. Specimens were stored frozen at (-20°C) for up to one month. 
3. Frozen sera were completely thawed and mixed well before estimation. 
REAGENT PRPARATION 
1. 20X Enzyme Conjugate: 1x working dilution at 1:20 with assay diluents 
was prepared eg, 0.1 ml of the stock conjugate in 1.9 ml of assay diluents 
is sufficient for 20 wells. The diluted conjugate was used on the same 
day. 
2. 20X Wash Buffer Concentrate: 1X wash buffer was prepared by adding 
the contents of the bottle to 475 ml of distilled water.  
ASSAY PROCEDURE 
Prior to assay regeants were allowed to stand at room temperature. 
 
Regeants were gently mixed before use. 
1. Place the desired number of coated strips into the holder. 
2. Pipette 25 µl of insulin standards, control and patient’s sera into 
appropriate wells. 
3. Add 100 µl of working Insulin Enzyme Conjugate to all wells. 
4. Thoroughly mix for 10 sec, it is important to have a complete mixing in 
this step. 
5. Incubate for 60 minutes at room temperature(18-26° C) 
6. Remove liquid from all wells. Wash wells three times with 300 µl of 1X 
wash buffer. Blot on absorbent paper towels. 
7. Add 100µl of stop TMB substrate to all wells. 
8. Incubate for 15 minutes at room temperature. 
9. Add 50 µl of stop solution to all wells. Shake the plate gently to mix the 
solution. 
10. Read absorbance on ELISA Reader at 450 nm within 15 minutes after 
adding the stopping solution. 
CALCULATION OF RESULTS 
The standard curve is constructed as follows. 
1. Check insulin standard value on each standard vial. 
2.  To construct the standard curve, plot the absorbance for the insulin 
standards (vertical axis) versus the insulin standard concentrations in 
µIU/mL (horizontal axis) on the linear graph paper. Draw the best curve 
through the points. 
3. Read the absorbance for controls and each unknown sample from the 
curve. Record the value for each control or unknown sample. 
4. Value above the highest point of the standard are related after diluting 
with “0” standard. 
EXPECTED VALUES 
The expected values of serum insulin using this ELISA kit was  <25 
µIU/mL . 
HOMA-IR: 
HOMA-IR was determined to measure the insulin resistance . 
HOMA IR=  (fasting serum insulin  in μU/mL  x  fasting plasma glucose  
       in mmol/L)/22.5 
CALCULATION OF BMI: 
Body mass index was determined by the following formula. 
BMI = Weight in kgs / Height in m² 
 
  
  
 
Statistical Analysis 
  
  
STATISTICAL ANALYSIS 
Statistical analysis was done using SPSS software version 17.0 
1. Descriptive statistics was derived for all the parameters given in the 
master chart for both cases and controls. 
2. Comparision was made using Chi-square test and Independent samples t-
test to find if there were any difference in all the parameters among 
hypertensives and apparently healthy controls.  P value taken as 
significant is less than 0.05.  
3. Distribution and frequencies of the genotypes between cases and controls 
were compared with a 2 test. 
4. The allele frequencies ( Class I &Class II) among cases and controls were 
calculated by allele counting. 
5. Chi square test was used to compare the allele proportions between cases 
and controls for 2*2 contingency table. 
6. Associated risk of essential hypertension and classI/classI genotype was 
calculated by using Odds ratio. 
7. Odds ratio was adjusted for BMI to know whether the association of 
LEP-tet polymorphism was independent of obesity. 
8. To know the relation between genotypes and serum leptin levels among 
hypertensives and apparently healthy controls ANOVA was used. 
9. Comparision between the insulin levels and mean HOMA-IR index 
among different genotypes was done with  ANOVA  
10. ANOVA was used to compare the relation between the genotypes and 
BMI among hypertensives and apparently healthy controls. 
11. Pearsons correlation test was used to detect the relation between serum 
leptin levels and HOMA-IR among cases and controls. 
12. To determine  if there is any relation of leptin concentrations to BMI 
among hypertensives and apparently healthy controls, Pearson correlation 
test was used. 
13. Correlation of concentrations of leptin to lipid parameters among the 
cases and controls were determined using Pearson correlation analysis . 
14. Linear regression analysis was done to determine any significant 
association between leptin and other confounding parameters like 
age,gender,BMI,smoking, alcohol and genotypes. 
15. Multiple logistic regression was carried out to determine any significant 
association of leptin gene polymorphism with essential hypertension after 
keeping the influence of the confounding variables as constant. 
16. Hardy-Weinberg principle calculation was done to check whether the 
genotypes of the study population was in Hardy-Weinberg equilibrium. 
 
  
  
Results 
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1 65 M 130 90 19.96 Y Y 86 40 1.2 99 200 30 150.2 I/II 0.71 0.071 0.02 
2 53 M 150 100 19.23 Y Y 82 28 0.7 76 180 40 124.8 I/II 2.4 0.07 0.01 
3 48 M 140 100 20.57 Y Y 89 34 0.9 121 186 35 126.8 I/I 1.4 11.3 2.48 
4 52 M 160 100 21.19 N Y 80 20 0.5 100 164 34 110 II/II 13.61 100.4 19.83 
5 48 M 140 100 22.31 N Y 89 34 0.9 69 192 41 137.2 I/II 14.4 2.18 0.48 
6 45 M 160 100 21.51 N N 102 42 1.3 71 208 39 154.8 I/I 6.1 42 10.58 
7 50 F 146 90 22.83 N N 100 36 1 90 198 41 139 II/II 48.9 13.98 3.45 
8 45 M 140 90 21.77 N N 76 24 0.6 88 164 38 108.4 I/II 1.67 0.14 0.03 
9 52 F 160 100 21.93 N N 86 38 1.1 82 200 38 145.6 I/II 38 7.74 1.64 
10 55 F 146 90 21.36 N N 100 38 1.1 105 152 45 86 II/II 57.43 2.22 0.55 
11 60 M 180 110 22.66 N N 94 40 1.2 119 163 35 104.2 I/I 7.2 3.15 0.73 
12 53 M 170 130 24.38 N Y 89 24 0.6 130 178 33 119 I/II 6.9 7.92 1.74 
13 47 M 146 90 24.14 N N 86 34 0.9 68 198 42 142.4 I/I 5.8 1.13 0.24 
14 46 M 180 110 23.99 N N 88 32 0.8 89 182 37 127.2 II/II 2.3 35.17 7.64 
15 56 M 160 110 24.77 N N 99 38 1.1 92 204 38 147.6 I/II 4.02 11.51 2.81 
16 57 M 150 100 24.77 Y Y 90 34 0.9 71 194 43 136.8 I/II 6.5 4.24 0.94 
17 60 M 140 90 23.59 N N 88 40 1.2 74 192 40 137.2 I/II 8.6 4.31 0.94 
18 55 M 150 100 24.03 Y Y 95 37 1 96 198 43 135.8 II/II 6.1 0.93 0.22 
19 50 M 160 90 24.98 N N 100 36 1 79 195 37 142.2 I/I 0.94 53.81 13.29 
20 47 M 170 100 23.42 Y N 80 34 0.9 76 194 41 137.8 I/II 5.05 1.12 0.22 
21 48 M 140 100 23.05 N N 85 34 0.9 89 194 43 133.2 II/II 4.8 0.61 0.13 
22 47 M 160 110 23.12 N N 80 24 0.6 280 170 32 82 I/II 2.6 0.27 0.05 
23 45 M 170 100 24.69 N N 88 30 0.8 176 192 33 123.8 II/II 5.1 8.61 1.87 
24 49 M 140 100 25.39 Y N 92 32 0.9 86 195 41 136.8 II/II 10.3 0.11 0.02 
25 64 F 140 90 26.28 N N 74 40 1.2 85 208 48 143 I/I 81.8 1.03 0.19 
26 47 M 130 100 25.95 Y Y 92 31 0.8 77 190 41 133.6 I/II 45.4 11.2 2.54 
27 51 M 146 110 27.44 Y Y 85 28 0.7 92 182 42 121.6 II/II 14 0.37 0.08 
28 53 M 140 100 28.95 Y Y 80 28 0.7 78 195 38 141.4 II/II 9.6 0.77 0.15 
29 58 F 140 100 29 N N 94 38 1.1 98 198 40 138.4 I/II 38.4 40.55 9.41 
30 60 F 160 120 29.52 N N 100 40 1.2 102 200 37 142.6 II/II 50.6 22.46 5.55 
31 59 M 160 120 25.71 N N 87 33 0.8 83 180 41 122.4 II/II 3.4 8.07 1.73 
32 58 M 180 11O 26.14 Y Y 97 36 0.9 160 174 38 104 I/I 51.1 1.12 0.27 
33 50 F 150 110 27.01 N N 100 32 1 171 196 35 126.8 II/II 42.6 14.17 3.50 
34 45 F 190 120 27.03 N N 90 36 1 96 192 43 129.8 II/II 52.2 0.71 0.16 
35 53 F 150 90 25.78 N N 84 30 0.8 114 182 31 128.2 I/II 50.3 6.18 1.28 
36 46 M 150 100 25.59 Y N 93 32 0.9 118 173 34 115.4 II/II 16.7 7.66 1.76 
37 48 F 110 80 27.39 N N 70 26 0.5 77 182 39 127.6 I/I 51.4 5.65 0.98 
38 46 M 150 100 27.85 N N 86 36 1 82 198 40 141.6 I/II 15.7 10.9 2.31 
39 65 F 170 100 28.4 N N 74 28 0.7 84 204 43 144.2 II/II 70.2 0.16 0.03 
40 39 F 140 90 29.38 N N 84 34 0.8 161 199 37 129.8 II/II 50.3 0.24 0.05 
41 57 F 140 100 29.34 N N 90 32 0.7 205 190 33 116 I/II 38.6 4.99 1.11 
42 50 M 140 100 28.2 N N 82 29 0.6 172 192 32 125.6 I/I 4.4 5.2 1.05 
43 54 M 130 90 25.1 N N 89 34 0.9 84 194 42 135.2 II/II 5.9 9.36 2.06 
44 55 M 148 96 27.27 Y N 82 27 0.8 190 188 32 118 II/II 9.4 1.65 0.33 
45 48 F 150 100 35.18 N N 83 29 0.9 165 194 43 118 I/II 65.9 11.98 2.46 
46 45 F 160 110 33.16 N N 100 32 0.9 92 195 40 136.6 I/II 41.2 58.7 14.49 
47 58 F 160 100 34.24 N N 100 38 1.1 211 204 31 130.8 I/II 63.5 6.25 1.54 
48 46 F 140 90 32.43 N N 86 32 0.8 176 186 35 115.8 I/II 79.1 1.27 0.27 
49 46 M 140 90 20.94 N N 80 32 0.8 110 189 34 133 I/I 7.9 5.76 1.14 
50 56 F 148 90 32.39 N N 97 36 1 120 198 36 138 II/II 90.9 52.87 12.66 
51 57 F 160 110 31.58 N N 98 38 1.1 107 206 36 148.6 II/II 131.5 16.39 3.97 
52 47 M 140 90 30.12 N N 88 32 0.8 102 187 38 128.6 I/I 21.1 1.11 0.24 
53 57 F 160 80 32.79 N N 101 38 1.1 89 198 42 138.2 I/II 99.9 51.45 12.83 
54 51 F 140 100 31.63 N N 100 36 1 67 196 44 138.6 II/II 113 19.67 4.86 
55 52 F 140 90 31.2 N N 89 28 0.7 98 182 43 119.4 I/I 103.5 7.42 1.63 
56 51 F 140 100 22.83 N N 76 23 0.6 151 137 32 74.8 I/II 15.5 6.87 1.29 
57 49 F 150 90 21.36 N N 80 24 0.7 88 123 46 59.4 II/II 30.35 4.31 0.85 
58 50 M 146 96 22.31 Y N 94 28 0.9 115 135 35 77 I/II 8.3 1.62 0.38 
59 45 M 150 90 22.66 Y Y 79 36 1 73 111 44 52.4 I/II 45.7 9.82 1.92 
60 61 M 152 94 23.4 Y N 96 28 0.9 88 198 38 142.4 II/II 38.4 40.55 9.61 
61 52 F 160 90 22.31 N N 82 24 0.7 90 189 39 132 I/I       
62 48 F 146 100 29 N N 94 38 1.1 98 198 40 138.4 II/II       
63 60 F 156 90 29.52 N N 100 40 1.2 102 200 37 142.6 I/II       
64 69 M 148 100 25.71 N N 87 33 0.8 83 180 41 122.4 I/II       
65 58 M 160 90 26.14 Y Y 97 36 0.9 160 174 38 104 II/II       
66 52 F 150 90 27.01 N N 100 32 1 171 196 35 126.8 II/II       
67 45 F 160 90 27.03 N N 90 36 1 96 192 43 129.8 I/II       
68 63 F 140 90 25.78 N N 84 30 0.8 114 182 31 128.2 II/II       
69 56 M 150 90 25.59 Y N 93 32 0.9 118 173 34 115.4 II/II       
70 68 F 140 100 27.39 N N 70 26 0.5 77 182 39 127.6 I/II       
71 46 M 150 90 27.85 N N 86 36 1 82 198 40 141.6 I/II       
72 65 F 140 90 28.4 N N 74 28 0.7 84 204 43 144.2 I/I       
73 49 F 150 90 29.38 N N 84 34 0.8 161 199 37 129.8 II/II       
74 57 F 150 100 29.34 N N 90 32 0.7 205 190 33 116 II/II       
75 50 M 140 90 28.2 N N 82 29 0.6 172 192 32 125.6 I/II       
76 54 M 142 92 25.1 N N 89 34 0.9 84 194 42 135.2 I/II       
77 65 M 158 96 27.27 Y N 82 27 0.8 190 188 32 118 II/II       
78 48 F 150 98 35.18 N N 83 29 0.9 165 194 43 118 I/II       
79 45 F 156 92 33.16 N N 100 32 0.9 92 195 40 136.6 II/II       
80 59 F 140 94 34.24 N N 100 38 1.1 211 204 31 130.8 I/II       
81 46 F 144 92 32.43 N N 86 32 0.8 176 186 35 115.8 II/II       
82 46 M 150 90 20.94 N N 80 32 0.8 110 189 34 133 II/II       
83 56 F 146 96 32.39 N N 97 36 1 120 198 36 138 I/I       
   
84 57 F 152 100 31.58 N N 98 38 1.1 107 206 36 148.6 I/II       
85 47 M 140 94 30.12 N N 88 32 0.8 102 187 38 128.6 I/II       
86 57 F 150 90 32.79 N N 101 38 1.1 89 198 42 138.2 II/II       
87 51 F 142 90 31.63 N N 100 36 1 67 196 44 138.6 I/II       
88 52 F 150 90 31.2 N N 89 28 0.7 98 182 43 119.4 II/II       
89 61 F 144 100 22.83 N N 76 23 0.6 151 137 32 74.8 I/II       
90 49 F 148 90 21.36 N N 80 24 0.7 88 123 46 59.4 I/II       
91 50 M 140 98 22.31 Y N 94 28 0.9 115 135 35 77 II/II       
92 45 M 150 92 22.66 Y Y 79 36 1 73 111 44 52.4 I/I       
93 61 M 156 92 23.4 Y N 96 28 0.9 88 198 38 142.4 I/II       
94 45 F 156 90 22.31 N N 82 24 0.7 98 188 38 130.4 I/II       
95 50 F 148 90 22.83 N N 100 36 1 90 198 41 139 II/II       
96 58 M 160 90 21.77 N N 76 24 0.6 88 164 38 108.4 I/II       
97 53 F 162 100 21.93 N N 86 38 1.1 82 200 38 145.6 I/II       
98 55 F 142 92 21.36 N N 100 38 1.1 105 152 45 86 I/II       
99 56 M 158 100 22.66 N N 94 40 1.2 119 163 35 104.2 I/I       
100 61 M 160 96 24.38 N Y 89 24 0.6 130 178 33 119 I/II       
MASTER CHART FOR HEALTHY CONTROLS 
S.no Age Sex 
Sys 
BP 
Dia 
BP BMI 
S
m
o
ki
n
g 
A
lc
o
h
ol 
Su
gar 
Ur
ea 
cre
ati
nin
e 
TG
L 
chole
stero
l 
HD
L LDL 
LEP 
GEN
OTY
PE Lept
in 
Insul
in 
HO
MA-
IR 
1 30 M 120 80 18.51 Y N 78 26 0.7 105 172 31 120 I/II 0.9 0.29 0.06 
2 49 M 120 80 19.53 N Y 86 34 0.9 110 196 36 138 I/II 0.73 0.69 0.15 
3 62 M 110 70 22.19 N N 82 38 1.1 121 206 32 149.8 I/II 1.8 14.67 2.97 
4 62 F 110 70 18.9 N N 98 28 1 83 204 42 145.4 II/II 5.6 0.01 0.00 
5 52 M 100 70 20.24 Y N 88 36 0.8 118 198 37 137.4 I/II 2.1 0.17 0.04 
6 37 M 110 70 19.95 Y N 78 24 0.7 65 144 39 92 II/II 0.8 0.27 0.05 
7 43 F 110 70 17.12 N N 98 34 0.9 115 196 37 136 I/II 4.5 6.95 1.68 
8 40 F 120 80 22.18 N N 79 32 0.6 140 192 38 126 II/II 3.9 4.85 0.95 
9 48 M 120 70 22.99 Y Y 90 30 1 225 198 33 120 II/II 2.7 0.66 0.15 
10 35 F 120 70 22.03 N N 92 32 0.8 113 184 34 127.4 II/II 5.5 0.89 0.20 
11 43 F 110 70 19.98 N N 90 33 0.9 80 192 39 137 II/II 4.3 7.07 1.57 
12 50 F 120 70 20 N N 94 26 0.5 68 137 42 81.4 II/II 10.8 0.88 0.20 
13 36 M 120 70 22.94 N N 90 30 0.8 103 188 32 135.4 I/II 5.1 0.78 0.17 
14 52 M 120 80 17.09 Y N 96 31 0.9 139 192 35 129.2 II/II 2.6 1.55 0.37 
15 32 F 110 70 20 N N 98 27 0.7 124 182 36 121.2 I/I 10.9 12.79 3.09 
16 45 F 110 70 18.59 N N 98 28 0.8 97 159 42 97.6 I/II 2.2 1.08 0.26 
17 45 M 110 70 23.28 N N 79 29 0.9 100 194 31 143 II/II 3.9 9.34 1.82 
18 38 M 120 80 26.08 Y Y 86 29 0.8 84 227 44 166.2 II/II 6.1 0.73 0.16 
19 47 M 120 80 26.71 Y N 76 25 0.6 70 196 47 135 II/II 5.2 1.74 0.33 
20 47 M 130 80 25.1 N Y 80 24 0.6 169 174 33 107.2 I/II 2.3 1.42 0.28 
21 43 F 120 80 24.34 N N 94 32 0.8 116 199 34 141.8 II/II 25 0.73 0.17 
22 45 M 120 80 25.61 Y N 90 34 0.7 72 222 45 162.6 I/II 14.7 10.69 2.38 
23 34 M 100 70 25.1 Y N 92 28 0.9 174 189 33 121.2 II/II 10.8 11.98 2.72 
24 39 F 120 80 26.67 N N 100 36 0.7 83 185 39 129.4 II/II 60.7 1.11 0.27 
25 52 F 120 80 29.64 N N 98 36 1 88 198 42 138.4 I/II 79.4 40.11 9.71 
26 44 F 120 70 28.76 N N 92 34 0.9 60 192 39 141 II/II 63.3 8.61 1.96 
27 46 F 120 80 24.89 N N 94 36 1 66 186 41 131.8 I/II 66.5 7.7 1.79 
28 47 M 120 70 25.15 Y Y 90 34 0.9 132 192 35 130.6 II/II 0.7 4.96 1.10 
29 48 M 110 70 38.54 Y N 88 32 0.8 80 198 39 143 II/II 82.5 28.4 6.17 
30 56 M 100 70 25.61 Y N 100 38 0.9 164 199 36 130.2 I/I 7.8 10.98 2.71 
31 60 M 120 70 22.03 N N 86 38 1.1 105 172 31 120 II/II       
32 55 M 110 70 23.28 N N 100 40 1.2 110 196 36 138 II/II       
33 50 M 120 70 24.34 N N 94 33 0.8 121 206 32 149.8 I/II       
34 47 M 120 70 17.09 N N 89 36 0.9 83 204 42 145.4 II/II       
35 48 M 100 70 26.08 N N 86 32 1 118 198 37 137.4 II/II       
36 47 M 120 80 22.94 N N 88 36 1 65 144 39 92 II/II       
37 45 F 120 80 19.53 N N 99 30 0.8 115 196 37 136 II/II       
38 49 M 120 80 26.08 N N 90 32 0.9 140 192 38 126 I/II       
39 64 F 120 70 18.9 N N 88 26 0.5 225 198 33 120 II/II       
40 47 F 110 70 20.24 N N 95 36 1 113 184 34 127.4 I/II       
41 51 M 100 70 19.95 N N 100 28 0.7 80 192 39 137 II/II       
42 53 M 120 80 23.28 Y N 80 34 0.8 68 137 42 81.4 I/II       
43 58 M 120 80 17.09 Y Y 85 32 0.7 103 188 32 135.4 II/II       
44 60 M 110 70 22.99 Y N 80 29 0.6 139 192 35 129.2 II/II       
45 59 M 110 70 25.15 N N 88 34 0.9 124 182 36 121.2 II/II       
46 58 M 100 70 22.19 N N 92 27 0.8 97 159 42 97.6 II/II       
47 50 M 110 70 22.03 N N 74 29 0.9 300 194 31 103 II/II       
48 45 M 110 70 19.98 N N 92 32 0.9 84 227 44 166.2 I/II       
49 53 M 120 80 26.08 N N 85 38 1.1 70 196 47 135 II/II       
50 46 M 120 70 22.94 N N 80 32 0.8 169 174 33 107.2 II/II       
51 48 M 110 70 17.09 N Y 94 32 0.8 116 199 34 141.8 II/II       
52 46 M 100 70 20 N N 100 36 1 72 222 45 162.6 I/II       
53 65 M 120 80 18.59 N N 87 38 1.1 174 189 33 121.2 II/II       
54 39 M 120 80 23.28 Y N 97 32 0.8 83 185 39 129.4 I/II       
55 57 F 120 80 23.28 N N 100 38 1.1 88 198 42 138.4 II/II       
56 50 M 120 80 18.9 N N 90 36 1 60 192 39 141 II/II       
57 54 M 130 80 25.1 N N 84 28 0.7 66 186 41 131.8 I/II       
58 55 M 120 80 24.34 N N 93 23 0.6 132 192 35 130.6 II/II       
59 48 F 120 80 25.61 N N 70 24 0.7 80 198 39 143 II/II       
60 45 F 100 70 25.1 N N 86 32 0.6 164 199 36 130.2 I/II       
61 58 M 120 80 26.67 N N 74 30 1 107 206 36 148.6 I/II       
62 46 M 120 80 29.64 N N 84 32 0.8 102 187 38 128.6 II/II       
63 46 F 120 70 28.76 N N 90 33 0.9 89 198 42 138.2 II/II       
64 56 F 120 80 24.89 N N 89 26 0.5 67 196 44 138.6 I/II       
65 57 F 120 70 25.15 N N 76 30 0.8 98 182 43 119.4 II/II       
66 47 M 110 70 38.54 N N 80 31 0.9 151 137 32 74.8 II/II       
67 57 F 100 70 22.94 N N 94 27 0.7 88 123 46 59.4 II/II       
68 51 M 100 70 22.03 Y N 79 28 0.8 115 135 35 77 II/II       
69 52 F 110 70 23.28 N N 96 29 0.9 73 111 44 52.4 I/II       
70 51 F 110 70 22.19 N N 82 29 0.8 88 198 38 142.4 II/II       
71 49 F 120 80 38.54 N N 94 34 0.9 98 188 38 130.4 II/II       
72 50 M 120 70 25.61 N N 100 32 0.8 90 198 41 139 II/II       
73 45 M 120 70 22.03 N N 87 38 0.9 88 164 38 108.4 I/II       
74 61 M 110 70 23.28 N N 97 38 1.1 82 200 38 145.6 II/II       
75 52 F 120 70 24.34 N N 100 40 1.2 105 152 45 86 II/II       
76 48 F 120 70 23.28 N N 90 34 0.9 119 163 35 104.2 II/II       
77 60 F 110 70 26.08 N N 84 36 0.8 130 178 33 119 II/II       
78 69 F 120 80 22.94 N N 93 24 0.7 89 198 42 138.2 I/II       
79 58 M 120 80 19.53 N Y 70 34 0.9 67 196 44 138.6 I/II       
80 52 F 130 80 26.08 N N 86 32 0.6 98 182 43 119.4 II/II       
81 45 F 120 70 18.9 N N 74 30 1 151 137 32 74.8 II/II       
82 63 M 110 70 20.24 N N 84 32 0.8 88 123 46 59.4 II/II       
83 56 F 120 70 19.95 N N 90 33 0.9 115 135 35 77 I/II       
84 68 F 120 70 23.28 N N 88 26 0.5 73 111 44 52.4 II/II       
  
TABLE – A 
 DESCRIPTIVE STATISTICS CASES CONTROLS 
A
G
E
 
N  VALID 100 100 
 MISSING 0 0 
MEAN 52.75 50.43 
STD. DEVIATION 6.254 7.846 
MINIMUM 39 30 
MAXIMUM 69 69 
S
B
P
 
N  VALID 100 100 
 MISSING 0 0 
MEAN 150.12 115.70 
STD. DEVIATION 11.772 7.420 
85 46 F 120 80 18.9 N N 100 30 0.8 88 198 38 142.4 II/II       
86 65 F 110 70 22.99 N N 86 31 0.9 90 189 39 132 I/II       
87 49 F 110 70 31.63 N N 100 27 0.7 98 198 40 138.4 II/II       
88 57 M 110 70 31.2 N N 94 28 0.8 102 200 37 142.6 II/II       
89 50 M 120 80 22.83 N N 89 29 0.9 83 180 41 122.4 II/II       
90 54 M 120 80 21.36 N N 86 29 0.8 160 174 38 104 II/II       
91 65 F 130 80 22.31 N N 88 25 0.6 171 196 35 126.8 I/II       
92 48 F 120 80 22.66 N N 99 24 0.6 96 192 43 129.8 I/II       
93 45 F 120 80 23.4 N N 80 32 0.8 114 182 31 128.2 II/II       
94 59 M 100 70 22.31 N N 85 25 0.6 118 173 34 115.4 II/II       
95 46 M 120 80 22.83 Y N 80 24 0.6 77 182 39 127.6 II/II       
96 46 F 120 80 21.77 N N 88 32 0.8 82 198 40 141.6 II/II       
97 56 F 120 70 21.93 N N 92 34 0.7 84 204 43 144.2 I/II       
98 57 F 120 80 21.36 N N 74 28 0.9 161 199 37 129.8 II/II       
99 47 M 120 70 25.1 Y N 92 36 0.7 205 190 33 116 I/I       
100 57 F 120 80 24.34 N N 85 36 1 172 192 32 125.6 II/II       
MINIMUM 110 100 
MAXIMUM 190 130 
D
B
P
 
N  VALID 100 100 
 MISSING 0 0 
MEAN 96.67 74.20 
STD. DEVIATION 8.379 4.960 
MINIMUM 80 70 
MAXIMUM 130 80 
B
M
I 
N  VALID 100 100 
 MISSING 0 0 
MEAN 26.32 23.36 
STD. DEVIATION 4.004 4.084 
MINIMUM 19 17 
MAXIMUM 35 39 
S
U
G
A
R
 
N  VALID 100 100 
 MISSING 0 0 
MEAN 88.82 88.65 
STD. DEVIATION 8.214 7.647 
MINIMUM 70 70 
MAXIMUM 102 100 
U
R
E
A
 
N  VALID 100 100 
 MISSING 0 0 
MEAN 32.44 31.37 
STD. DEVIATION 5.058 4.192 
MINIMUM 20 23 
MAXIMUM 42 40 
C
R
E
A
T
IN
IN
E
 
N VALID 100 100 
 MISSING 0 0 
MEAN .88 .83 
STD. DEVIATION .186 .158 
MINIMUM 0 0 
MAXIMUM 1 1 
 
 DESCRIPTIVE STATISTICS CASES CONTROL 
T
G
L
 
N  VALID 100 100 
 MISSING 0 0 
MEAN 112.58 110.00 
STD. DEVIATION 41.205 40.458 
MINIMUM 67 60 
MAXIMUM 280 300 
C
H
O
L
E
S
T
E
R
O
L
 
N  VALID 100 100 
 MISSING 0 0 
MEAN 184.62 184.27 
STD. DEVIATION 20.934 23.589 
MINIMUM 111 111 
MAXIMUM 208 227 
H
D
L
 
N  VALID 100 100 
 MISSING 0 0 
MEAN 38.23 37.98 
STD. DEVIATION 4.221 4.325 
MINIMUM 30 31 
MAXIMUM 48 47 
L
D
L
 
N  VALID 100 100 
 MISSING 0 0 
MEAN 123.87 124.29 
STD. DEVIATION 22.107 23.958 
MINIMUM 52 52 
MAXIMUM 155 166 
L
E
P
T
IN
 
N  VALID 60 30 
 MISSING 40 70 
MEAN 31.58 16.44 
STD. DEVIATION 32.397 25.340 
MINIMUM 1 1 
MAXIMUM 132 82 
IN
S
U
L
IN
 
N  VALID 60 30 
 MISSING 40 70 
MEAN 12.59 6.40 
STD. DEVIATION 18.985 8.951 
MINIMUM 0 0.01 
MAXIMUM 100 40 
H
O
M
A
IR
 
N  VALID 60 30 
 MISSING 4023.958 70 
MEAN 2.882854E0 1.449002E0 
STD. DEVIATION 4.3154274E0 2.0886774E0 
MINIMUM .0142 .0024 
MAXIMUM 19.8321 9.7056 
 
 
  
TABLE - B 
 
DESCRIPTIVE 
STATISTICS 
CASES CONTROLS 
S
E
X
 
 VALID 
MALE 
FEMALE TOTAL VALID 
MALE 
FEMALE TOTAL 
FREQUENCY 51 49 100 56 44 100 
PERCENT 51.0 49.0 100.0 56.0 44.0 100.0 
VALID 
PERCENT 
51.0 49.0 100.0 56.0 44.0 100.0 
CUMULATIVE 
PERCENT 
51.0 100.0  56.0 100.0  
 
DESCRIPTIVE 
STATISTICS 
CASES CONTROLS 
S
M
O
K
IN
G
 
 VALID 
YES 
VALID 
NO 
TOTAL VALID 
YES 
VALID 
NO 
TOTAL 
FREQUENCY 22 78 100 19 81 100 
PERCENT 22.0 78.0 100.0 19.0 81.0 100.0 
VALID 
PERCENT 
22.0 78.0 100.0 19.0 81.0 100.0 
CUMULATIVE 
PERCENT 
22.0 100.0  19.0 100.0  
 
DESCRIPTIVE 
STATISTICS 
CASES CONTROLS 
A
L
C
O
H
O
L
 
 VALID 
YES 
VALID 
NO 
TOTAL VALID 
YES 
VALID 
NO 
TOTAL 
FREQUENCY 16 84 100 8 92 100 
PERCENT 16.0 84.0 100.0 8.0 92.0 100.0 
VALID 
PERCENT 
16.0 84.0 100.0 8.0 92.0 100.0 
CUMULATIVE 
PERCENT 
16.0 100.0  8.0 100.0  
 
DESCRIPTIVE 
STATISTICS 
CASES CONTROLS 
L
E
P
T
IN
G
E
N
E
 
 VALI
D 
 I/ I 
II/ II I/ II TOT
AL 
VALI
D 
 I/ I 
II/ 
II 
I/ II TOTAL 
FREQUENCY 17 39 44 100 3 66 31 100 
PERCENT 17.0 39.0 44.0 100.0 3.0 66.0 31.0 100.0 
VALID 
PERCENT 
17.0 39.0 44.0 100.0 3.0 66.0 31.0 100.0 
CUMULATIVE  
PERCENT 
17.0 56.0 100.0  3.0 69.0 100.
0 
 
 
 
TABLE 1 
 
CHI-SQUARE TEST TO COMPARE THE PROPORTIONS BETWEEN 
CASES AND CONTROLS 
 
Variables 
Group 
Total 
P-Value Controls Cases 
N % N % N % 
LEP GENOTYPE 
II/II 66 66.0 39 39.0 105 52.5 
<0.001 I/II 31 31.0 44 44.0 75 37.5 
I/I 3 3.0 17 17.0 20 10.0 
Gender 
Male 56 56.0 51 51.0 107 53.5 
0.478 
Female 44 44.0 49 49.0 93 46.5 
Smoking 
No 81 81.0 78 78.0 159 79.5 
0.599 
Yes 19 19.0 22 22.0 41 20.5 
Alcohol 
No 92 92.0 84 84.0 176 88.0 
0.082 
Yes 8 8.0 16 16.0 24 12.0 
Total 100 100.0 100 100.0 200 100.0  
 
 
 
TABLE 2 
INDEPENDENT SAMPLES T-TEST TO COMPARE THE MEAN VALUES 
BETWEEN CASES AND CONTROLS 
 
variables Group N Mean Std. Dev t-Value P-Value 
Age 
Controls 100 50.43 7.846 
2.312 0.022 
Cases 100 52.75 6.254 
Sys BP 
Controls 100 115.70 7.420 
24.736 <0.001 
Cases 100 150.12 11.772 
Dia BP 
Controls 100 74.20 4.960 
23.081 <0.001 
Cases 100 96.80 8.442 
BMI 
Controls 100 23.36 4.084 
5.164 <0.001 
Cases 100 26.32 4.004 
Sugar 
Controls 100 88.65 7.647 
0.151 0.880 
Cases 100 88.82 8.214 
Urea 
Controls 100 31.37 4.192 
1.629 0.105 
Cases 100 32.44 5.058 
Creatinine 
Controls 100 .83 .158 
2.379 0.018 
Cases 100 .88 .186 
TGL 
Controls 100 110.00 40.458 
0.447 0.656 
Cases 100 112.58 41.205 
Cholesterol 
Controls 100 184.27 23.589 
0.111 0.912 
Cases 100 184.62 20.934 
HDL 
Controls 100 37.98 4.325 
0.414 0.680 
Cases 100 38.23 4.221 
LDL 
Controls 100 124.29 23.958 
0.128 0.899 
Cases 100 123.87 22.107 
Leptin Controls 30 16.44 25.340 2.486 0.015 
 Cases 60 31.98 32.520   
Insulin Controls 30 6.40 8.951 2.123 0.037 
 Cases 60 12.69 19.127   
HOMA-IR Controls 30 1.4490 2.08868 2.153 0.034 
 Cases 60 2.9099 4.34664   
 
TABLE -  3 
 
LEP 
GENOTYPE 
CONTROLS CASES 
P VALUE 
II/II 66 39  
 
<0.001 
I/II 31 44 
I/I 3 17 
 
 
 
TABLE - 4 
CHI-SQUARE TEST TO COMPARE THE ALLELE PROPORTIONS 
BETWEEN CASES AND CONTROLS 
Variables Group Total P-Value 
Controls Cases 
N % N % N % 
Allele Type 
II 163 81.5 122 61.0 285 71.3 
<0.001 
I 37 18.5 78 39.0 115 28.7 
Total 200 100.0 200 100.0 400 100.0  
 
 
Frequency of Class I allele in hypertensives  = 39 % 
Frequency of Class I allele in normotensives = 18.5% 
 
  
  
 
 
TABLE - 5 
ASSOCIATION BETWEEN ALLELES AND HYPERTENSION 
 CASES CONTROLS CASES+CONTROLS 
Class I 78 37 115 
Class II 122 163 285 
I+II 200 200 400 
 
O.R. =2.81657 
 
Wald 95% CI: 1.785 >2.817> 4.445 
Chi-square value 20.5156 
p-value< 0.0001 
TABLE 6(A) 
To find an association between CLASS I/ CLASS I 
genotype  and 
Essential hypertension. 
GENOTYPE Hypertension  
Yes No Total 
CLASS I/ 
CLASS I 
Yes 17 3 20 
No 83 97 180 
Total 100 100 200 
Odds ratio = ad/bc 
= 6.62 (95% CI, 1.88 – 23.39) 
Mantel Haenszel Chi –square = 10.834, p value = 0.001 
TABLE 6(B) 
 
 
Odds ratio after adjusting BMI = 1.206 (95% CI, 1.113 – 1.307) 
P = 0.000 
 
 
 
 
Parameter Estimates 
Hypertension
a
 B Std. Error Wald df Sig. Exp(B) 
95% Confidence Interval for 
Exp(B) 
Lower Bound Upper Bound 
1 Intercept -4.625 1.018 20.630 1 .000    
BMI .187 .041 20.752 1 .000 1.206 1.113 1.307 
[Lepgenecode= ] 0
b
 . . 0 . . . . 
a. The reference category is:           2.       
b. This parameter is set to zero because it is redundant.      
TABLE – 7 
 
ONE WAY ANOVA TO COMPARE THE MEAN VALUE BETWEEN GENO 
TYPES 
 
Variables  N Mean Std. Dev Min Max P-Value 
Leptin 
II/II 41 28.59 33.20 0.70 131.50 
0.883 
I/II 35 25.10 28.36 0.71 99.90 
I/I 14 25.81 33.01 0.94 103.50 
Total 90 26.80 31.06 0.70 131.50 
Insulin 
II/II 41 10.86 18.72 0.01 100.40 
0.940 
I/II 35 9.88 14.66 0.07 58.70 
I/I 14 11.60 16.05 1.03 53.81 
Total 90 10.60 16.66 0.01 100.40 
HOMA-IR 
II/II 41 2.42 3.972 0.00 19.83 
0.929 
I/II 35 2.29 3.592 0.01 14.49 
I/I 14 2.76 4.036 0.19 13.29 
Total 90 2.42 3.798 0.00 19.83 
BMI 
II/II 105 24.84 4.468 17.09 38.54 
0.932 
I/II 75 24.75 4.269 17.12 35.18 
I/I 20 25.16 3.607 20.00 32.39 
Total 200 24.84 4.297 17.09 38.54 
 
 TABLE – 8 
 
CORRELATION ANALYSIS 
 
  Leptin HOMA-IR BMI 
Leptin 
Correlation  0.269 0.694 
P-Value  0.010 <0.001 
N  90 90 
HOMA-IR 
Correlation 0.269  0.283 
P-Value 0.010  0.007 
N 90  90 
BMI 
Correlation 0.694 0.283  
P-Value <0.001 0.007  
N 90 90  
 
 
 
 
 
 
 TABLE - 9 
 
 
CORELATIONS  CASES CONTROLS 
  
 
LEPTIN 
         LDL 
 PEARSON SIG. 
 (2- 
TAILED) 
N PEARSON SIG. 
 (2- 
TAILED) 
N 
LEPTIN 1  61 1  30 
LDL .086 .510 61 .196 .299 30 
LEPTIN .086 .510 61 .196 .299 30 
LDL 1  100 1  100 
 
 
CORELATIONS  CASES CONTROLS 
  
 
LEPTIN 
         HDL 
 PEARSON SIG. 
 (2- 
TAILED) 
N PEARSON SIG. 
 (2- 
TAILED) 
N 
LEPTIN 1  61 1  30 
HDL .247 .055 61 .295 .114 30 
LEPTIN .247 .055 61 .295 .114 30 
HDL 1  100 1  100 
 
 
CORELATIONS  CASES CONTROLS 
   PEARSON SIG. 
 (2- 
N PEARSON SIG. 
 (2- 
N 
 LEPTIN 
         TGL 
TAILED) TAILED) 
LEPTIN 1  61 1  30 
TGL .039 .764 61 -.392* .032 30 
LEPTIN .039 .764 61 -.392* .032 30 
TGL 1  100 1  100 
*. CORRELATION IS SIGNIFICANT AT THE 0.05 LEVEL (2- TAILED) 
 
CORELA
TIONS 
 CASES CONTROLS 
  
 
LEPTIN 
         
CHOLEST
EROL 
 PEARSO
N 
SIG. 
 (2- 
TAILED) 
N PEARS
ON 
SIG. 
 (2- 
TAILED) 
N 
LEPTIN 1  61 1  30 
CHOLESTEROL .163 .209 61 .100 .599 30 
LEPTIN .163 .209 61 .100 .599 30 
CHOLESTEROL 1  100 1  100 
 
**. CORRELATION IS SIGNIFICANT AT THE 0.01 LEVEL (2- TAILED) 
TABLE – 10  
REGRESSION ANALYSIS FOR LEPTIN 
MODEL SUMMARY 
Model R R Square Adjusted R Square 
1 0.845
a
 0.714 0.693 
 
Predictors 
Regression Co-
Efficient (Beta) 
Std. Error 
(Beta) 
95.0% CI for Beta 
P-Value 
Lower Bound Upper Bound 
(Constant) -150.923 16.537 -183.814 -118.032  
Age 0.504 0.258 -0.008 1.017 0.054 
Gender 35.027 4.807 25.466 44.588 <0.001 
BMI 3.956 0.455 3.050 4.862 <0.001 
Smoking 7.503 5.076 -2.593 17.599 0.143 
Alcohol 2.427 5.255 -8.024 12.878 0.645 
LEP GENOTYPE 2.092 2.608 -3.096 7.279 0.425 
 
TABLE - 11 
MULTIPLE LOGISTIC REGRESSION ANALYSIS FOR CASES (HTN) 
Factors 
Adj OR 
95% CI for OR 
P-Value 
LL UL 
Age 1.052 1.004 1.102 0.034 
Gender Male 1.000    
Female 0.792 0.362 1.734 0.559 
BMI 1.256 1.141 1.383 <0.001 
LEP GENOTYPE II/II 1.000    
I/II 2.723 1.364 5.435 0.004 
I/I 13.860 3.310 58.044 <0.001 
Smoking No 1.000    
Yes 1.306 0.501 3.401 0.585 
Alcohol No 1.000    
Yes 3.319 1.073 10.267 0.037 
TGL 0.998 0.987 1.010 0.772 
HDL 0.989 0.890 1.100 0.842 
LDL 0.991 0.976 1.006 0.227 
 
 
 
 
 
TABLE - 12 
HARDY-WEINBERG EQUILIBRIUM 
Variables 
Group 
P-Value Observed Expected 
N % N % 
LEP GENOTYPE 
II/II 105 52.5 101.5 50.8 
0.709 I/II 75 37.5 82.0 41.0 
I/I 20 10.0 16.5 8.2 
Total 200 100 200 100  
 
 
 
 
 
 
 
 
RESULTS 
The estimated levels of various biochemical parameters namely fasting 
plasma glucose, serum urea, serum creatinine, plasma triglycerides, plasma total 
cholesterol, plasma HDL, calculated LDL, fasting serum leptin, fasting serum 
insulin, HOMA-IR levels along with calculated BMI, exposure to smoking and 
alcohol all of which are risk factors for essential hypertension were tabulated 
separately for cases and controls in  Master chart no.1 – hypertensive subjects 
and Master chart no.2 – apparently healthy controls. 
Descriptive statistics Tables - (A,B) provide information about the 
descriptive statistics of age, sex, systolic BP, diastolic BP, BMI, smoking, 
alcohol, biochemical parameters like fasting plasma glucose, serum urea, serum 
creatinine, plasma lipid profile, leptin genotype, serum leptin, serum insulin, 
HOMA-IR. 
CASES :  
Age : 52.8 ± 6.3 years 
Sex : male:51, female:49 
BMI:26.3 ± 4 kg/m² 
Systolic BP: 150 ± 11 mm of Hg 
Diastolic BP: 96 ± 8 mm of Hg 
Controls : 
Age :50.4 ± 7.8 years 
Sex : male:56, female: 44 
BMI:23.36 ± 4 kg/m² 
Systolic BP: 115 ± 7 mm of Hg 
Diastolic BP: 74 ± 4 mm of Hg 
           
Table 1: shows comparision of the means of various parameters between 
cases and controls using Chi-Square test. Significant difference (Pvalue <0.001) 
was observed between the genotype distribution among cases and controls.  
Table 2: shows comparision of the means of various parameters between 
cases and controls using Independent samples t-test. Significant difference were 
observed many parameters like age,BP,serum creatinine, serum leptin,insulin 
and HOMA-IR. 
Table 3:  depicts the distribution of genotypes &  their frequencies among 
hypertensives and apparently healthy controls. The genotype frequencies when 
both cases and controls were combined were I/I = 20, I/II =75 and II/II = 105. 
The genotype  distribution and allele frequencies were strikingly different 
among cases and controls. Class I/classI genotype was relatively higher in cases 
and than controls and had a significant p value (17% against 3 % ; p value = 
0.001) 
The alleles of the LEP-tet polymorphism in the 3’-UTR of LEP gene 
consisted of  2 groups of various sized alleles: shorter form (class I) and longer 
form (class II)
230
. 
Table 4:  depicts the allele frequencies ( Class I &Class II) among 
hypertensives and apparently healthy controls. 
Class I allele was more frequent in hypertensives than in controls (39.0% 
vs. 18.5%;P <0.001). 
Table 5:  shows a significant relation of class I allele to its associated risk 
of essential hypertension with an odds =2.81657 and a P-value< 0.0001 (Wald 
95% CI: 1.785 >2.817> 4.445) 
Table 6(A):  shows significant association between class I / class I 
genotype and essential hypertension (Odds ratio = 6.62 (95% CI, 1.88 – 
23.39);p value = 0.001). 
Table 6(B):   This association was still significant with a P value = 0.000 
even after adjusting for BMI.  Odds ratio after adjusting BMI = 1.206 (95% 
confidence interval, 1.113 – 1.307). 
Table 7: shows One way ANOVA to compare the means of serum 
leptin,serum insulin, HOMA-IR and BMI between the genotypes. None of the 
above parameters were statistically significant. 
Table 8: shows the determination of correlation between serum leptin 
levels, HOMA-IR and BMI using Pearson correlation analysis. Serum leptin 
levels correlated significantly with HOMA-IR and BMI with a P value of 0.010 
and 0.001 respectively. Also HOMA-IR and BMI showed a significant 
correlation with a P value of 0.007. 
         Table 9 : shows the evaluation  of any correlation between serum leptin 
levels and lipid parameters by Pearson correlation  and no significant 
correlation were found . 
Table 10 : shows Multiple linear regression analysis for serum leptin 
levels with various explanatory variables. Serum leptin levels depends linearly 
with female sex and BMI with P values of <0.001 in both. 
Table 11 : shows Multiple logistic regression analysis for cases with 
hypertension. It showed that age, BMI, alcohol, Class I/Class I genotype and 
Class I/Class II(P value = 0.004) genotype had independent risks for 
hypertension. Also it indicated that Class I/Class I genotype with a P value of 
<0.001 was a significant and independent predictor of hypertension.  
Table 12: shows Hardy-Weinberg principle calculation. The genotype 
and allele distribution were found to be in Hardy-Weinberg equilibrium with a P 
value of 0.709. 
  
 
 
            
              Discussion 
DISCUSSION 
The association of tetranucleotide (TTTC)n repeat polymorphism at 3’-
UTR of  leptin gene  with essential hypertension was examined in this study. 
The ranges of fasting plasma glucose, serum urea and creatinine, fasting plasma 
lipid profile including triglycerides (TGL), total cholesterol (TC), HDL-C and 
LDL-C and serum insulin and leptin among the apparently healthy controls in 
this study were analysed  
  Fasting Plasma Glucose    = 88.7  ±  7.6 
  Serum Urea    = 31.4  ±  4.2 
  Serum Creatinine   = 0.83  ±  0.16 
  Plasma  Triglycerides  = 110  ±  40.61 
  Total Cholesterol   = 184.27 ± 23.59 
  Plasma  HDL   = 37.98 ± 4.33 
  Plasma  LDL   = 124.99 ± 23.96 
  Body Mass Index   = 23.36 ± 4.08 
  Serum insulin    = 3.35  ±  4.68 
Serum leptin(males-BMI<23)    =            2.09 ± 1.45  
Serum leptin(females-BMI<23)  =            5.96 ± 3.19 
HOMA-IR                                  = 1.45 ± 2.09 
 
- It is a recognized fact that leptin correlates well with amplified adiposity57 
.  This was true in our study. We observed that correlation of leptin 
concentrations and body mass index in both hypertensives (pearson 
correlation=0.678,p=0.000) and apparently healthy controls (pearson 
correlation=0.730,p=0.000) were significant. Thus as expected, positive 
association  was obtained between leptin and measures of increased 
adiposity.  
- The difference between serum leptin levels among hypertensives and 
apparently healthy controls in our study was statistically significant . This 
difference in leptin levels in both the hypertensive cases and  
normotensive controls was in line with many other studies. Leptin levels 
were reported to be elevated and positively correlated in hypertensives 
than normotensives in many studies
178,231-236
. In contrast few other studies 
couldn’t obtain a direct positive association between leptin and blood 
pressure
219,237
 . 
- Correlation of serum leptin levels and lipid parameters were not 
significant. 
- Serum leptin levels correlated significantly with female gender and BMI. 
This positive  correlation with female gender matched with the data from 
various studies revealing the sexual dimorphism exhibited by leptin.  
- Distribution of class I/class I and class I/classII genotypes were 
significantly higher in hypertensives than in normotensives. Individuals 
with shorter class I allele of LEP-tet polymorphism was found to be 
significantly associated with hypertension. This was in accordance to the 
results of similar studies
219,220
.   
-  Class I/Class I genotype and Class I/Class II(P value = 0.004) genotype 
had independent risks for hypertension. Though  Class I/Class I genotype 
with a P value of <0.001 was a significant and independent predictor of 
hypertension, the confounding variables like serum leptin, insulin and 
HOMA-IR could not be excluded because the sample size taken for their 
estimations were smaller to include them in the multiple logistic 
regression. This was found to be a limitation to this study. 
-  The significant association of this tetranucleotide repeat polymorphism 
with raised blood pressure was not linked to the measure of obesity 
calculated by body mass index. This was concluded with an odds of  
1.206  which was still significant with a P value of 0.000 even after 
adjusting for BMI. These outcomes put forward the conclusion that 
though this polymorphism was significantly related to hypertension, this 
association was not linked to obesity. The above finding supports an 
animal study  where chronic hyperleptinemia directs to a considerable 
rise in bp independent of obesity
238
. 
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- Quite  a few mechanisms apart from obesity could have been an interlink 
between this polymorphism and EH. Amongst them are insulin resistance 
and hyperinsulinemia. Hypertension has been linked to insulin resistance 
and hyperleptinemia seems to be a cause for IR. Nevertheless  IR was not 
statistically significant among different genotypes. Thus IR is unlikely to 
be the interlink. Also this polymorphism was not associated with T2DM 
an insulin-resistant state
230
. 
- This study also assessed the association of leptin gene polymorphism 
with hypertension via its effect on the serum leptin level. We didn’t find 
any significant correlation between serum leptin levels and hypertensives  
among any of the three genotypes. This finding is in line with few other 
studies
219,223
.  
Possible mechanisms: 
Thus as the phenotypic expression -leptin levels had no significant 
alterations due to this LEP- tet polymorphism the possible hypotheses to 
substantiate our observation are as follows. 
1. There is  a probability  that the different alleles of the LEP-tet 
polymorphism  may not have a functional role in determining the 
concentration of serum leptin levels. However additional studies are 
needed to prove this hypothesis. 
2. Another possibility could be a differential expression of leptin at different 
sites due to this polymorphism. Leptin  expression in nonadipose tissues 
have been demonstrated by some studies 
239,240
. Also studies have 
revealed a possibility of confined action of leptin via autocrine and 
paracrine manners. Thus this polymorphism could have resulted in 
increased expression of leptin at sites responsible for activating the 
sympathetic nervous system. Such an increased focal non circulating 
leptin levels could have been accountable for our observation by being 
responsible for hypertension despite no correlation between serum leptin 
levels and LEP-tet polymorphism.Additional research works are needed 
to shed light on this likelihood. 
3. Another possibility is the linkage disequilibrium of this polymorphism 
with some other familiar polymorphisms or mutations either on the 
coding or regulatory areas of  LEP or adjacent  genes. Yet, such 
mutations are very rare in the coding region of leptin gene 
241,242
. 
Additional studies are needed to conclude whether this association is 1° 
or 2° caused by linkage disequilibrium with some other mutations on the 
regulatory region of leptin gene or its proximity genes. 
 
 
  
  
           Conclusion   
CONCLUSION 
Differences among the study designs,  distributions of hypertension, as 
well as ethnic and racial differences across study populations may account for 
the absence of consistency in various other similar studies. 
Leptin is thought to produce hypertension by increasing the renal 
sympathetic activity along with decreased natriuresis
203,204
. Leptin controls the 
sympathetic nervous system activity in a tissue-specific manner
243
. 
Though leptin levels were same among both hypertensives and 
normotensives with raised BMI, this tetranucleotide repeat polymorphism was 
found to be directly and positively associated with essential hypertension 
independent of obesity, insulin resistance and hyperinsulinemia. 
Usually genetic association studies frequently fall short in reproducing 
results alike previous research works. To some extent this could be attributed to 
the polygenetic basis of the disease or to the difference among the investigated 
populations. The present observations on the genetic background 
of EH emphasize the call for further research works  in determining the 
complex, polygenetic basis and also gene-gene- and gene-environment 
interactions or a notable functional testing of the phenotype .  
 
 
  
  
Future Prospects of the    
Study  
 SCOPE FOR FUTURE STUDY 
• The LEP at chromosome 7q appears as a striking objective for additional 
researches  on linkage analysis. 
•  Further studies can be done on linkage disequilibrium genetic mapping 
and its association with essential hypertension. 
• With further studies LEP gene could be used as a marker gene for EH. 
• LEP and leptin are notable targets for further research works in defining 
the basis of EH and to elucidate the techniques in the screening, 
prevention, and treatment of EH. 
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ABBREVIATION 
 
ACE - Angiotensin Converting Enzyme 
AgRP - Agouti-Related Protein 
AMPK - AMP-activated Protein Kinase 
ARC - Arcuate nucleus 
BAT - Brown Adipose Tissue 
BMI - Body Mass Index 
BP -      Blood pressure 
CAD - Coronary Artery Disease 
CART - Cocaine-and Amphetamine-Regulated Transcript 
CHF - Congestive Heart Failure 
CHOL – Cholesterol 
CKD - Chronic Kidney Disease 
CNS - Central Nervous System 
CRF - Corticotropin Releasing Factor 
CVD - Cardio Vascular Disorders 
DASH - Dietary Approaches to Stop Hypertension 
DBP - Diastolic Blood Pressure 
DM – Diabetes Mellitus 
DMH - Dorso-Medial Hypothalamus 
DNA - Deoxyribo Nucleic Acid 
ECF - Extra Cellular Fluid 
EDHF - Endothelium Derived Hyperpolarizing Factor 
EDTA – Ethylene Diamine Tetra Acetic Acid 
EH                   -      Essential Hypertension 
ESRD - End Stage Renal Disease 
GLDH - Glutamate Dehydrogenase 
HDL  – High Density Lipoprotein 
HOMA-IR - Homeostatic Model Assessment –Insulin Resistance 
HRP - Horse Radish Peroxidase 
HT -  Hypertension 
IGF - Insulin like Growth Factor 
IRS2 - Insulin Receptor Substrate 2 
JAK - Janus Kinase 
JNC - Joint National Committee 
LEP - Leptin gene 
LEP-tet - Leptin gene tetranucleotide repeat polymorphism 
LDL – Low Density Lipoprotein 
LR - Leptin Receptor 
LVH - Left Ventricular Hypertrophy 
MAPK - Mitogen-Activated Protein Kinase 
MCR - MelanoCortin Receptors 
MSH - Melanoctye Stimulating Hormone 
NIDDM - Non Insulin Dependent Diabetes Mellitus 
NO - Nitric Oxide 
NPY - NeuroPeptide Y 
NTS - Nucleus Tractus Solitarius 
OCP - Oral Contraceptive Pills 
PAD - Peripheral Arterial Disease 
 PCOS - Poly Cystic Ovarian Syndrome 
PI3K - Phospho-Inositide-3-Kinase 
POMC - Pro-Opio MelanoCortin 
PTB1b - Protein Tyrosine Phosphatase 1b 
PVN - Para-Ventricular Nucleus 
QTL -        Quantitative Trait Loci  
RAAS - Renin Angiotensin Aldosterone System 
RSNA - Renal Sympathetic Nervous Activity 
SBP - Systolic Blood Pressure 
SNS - Sympathetic Nervous System 
STAT - Signal Transducer and Activator of Transcription 
SOCS-3 - Suppressors Of Cytokine Signaling protein 
TGL – Triglyceride 
TMB - Tetra Methyl Benzidine 
Tyr - Tyrosine 
UTR - Un-Translated Region 
VLDL  – Very Low Density Lipoprotein 
VMH - Vento-Medial Hypothalamus 
 
  
  
 
PATIENT CONSENT FORM 
Title of the study : ASSOCIATION OF LEPTIN GENE POLYMORPHISM IN  
ESSENTIAL HYPERTENSION”  
 
Name :       Date  : 
 
Age :       OP No : 
 
Sex :      Project Patient No : 
 
The details of the study have been provided to me in writing and explained to me in 
my own language. 
I confirm that I have understood the above study and had the opportunity to ask 
questions. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without the medical care that will 
normally be provided by the hospital being affected. 
I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). 
I have been given an information sheet giving details of the study. 
I fully consent to participate in the above study.                                                                                                                 
 
                                                                                                                Signature 
 
 
                                                    PROFORMA 
NAME : 
AGE     : 
SEX     : 
OP.NO: 
C/O: 
 
 
PAST HISTORY: 
DM: 
DISORDERS OF CVS, THYROID, NEUROLOGICAL, RENAL, ADRENAL, 
HEPATIC, GI 
OBSTUCTIVE SLEEP APNEA: 
RECENT INFECTION, INFLAMMATION, LIPID LOWERING DRUGS, NSAIDS, 
HRT(1 MONTH) 
NEUROFIBROMATOSIS, SCLERODERMA 
 
ERSONAL HISTORY: SMOKING      ALCOHOL         
MENSTRUAL HISTORY: 
FAMILY HISTORY: 
TREATMENT HISTORY: 
BP:           /          mmHg         PR:          /min 
WT:           KGS           HT:            CMS             BMI:  
INVESTIGATION  REPORTS: 
LAB RESULTS: 
 
 ECHO: 
 
TO BE MEASURED: 
PLASMA GLUCOSE: 
BLOOD UREA           : 
S.CREATININE         : 
TOTAL CHOLESTEROL: 
TGL                            : 
HDL                           : 
LEPTIN                     : 
INSULIN                   : 
 
PCR RESULTS        : 
ஆராய்ச்சி      தாள். 
  தங்களது   இரத்தம் இங்கு பெற்றுக் பகாள்ளப்ெட்டது. 
பசன்னை  அரசு பொது  மருத்துவமனைக்கு வரும் ந ாயாளிகளிடம் 
இருக்கும் உயர் இரத்த அழுத்த ந ாயில் பெப்டின் மரெணுவின் 
 நவறுொனட அறிய நமற்பகாள்ளப்ெடும்  ஆராய்ச்சி இங்கு  னடபெற்று 
வருகின்றது. 
    உயர் இரத்த அழுத்த ந ாயின் காரணங்கள் ெெ உள்ளை. அவற்றுள் 
ஒரு மரெணுவின் நவறுொடு ஒரு காரணமாக இருக்கொம் என்ெனதக் 
கண்டுெிடிப்ெநத இவ்வாரய்ச்சியின் ந ாக்கமாகும். 
     ீங்களும் இந்த ஆராய்ச்சியில் ெங்நகற்க  ாங்கள் விரும்ெிகிநறாம் .இந்த 
ஆராய்ச்சியில்  உங்களுனடய இரத்தத்னத எடுத்து சிெ  சிறப்புப் ெரிநசாதனைக்கு 
உட்ெடுத்தி அதன் தகவல்கனள ஆராய்நவாம்.  அதைால்  தங்களது ந ாயின் 
ஆய்வறிக்னகநயா அல்ெது  சிகிச்னசநயா ொதிப்புக்கு ஏற்ெடாது என்ெனதயும் 
பதரிவித்துக்பகாள்கிநறாம். 
    முடிவுகனள அல்ெது கருத்துக்கனள பவளியிடும் நொநதா அல்ெது 
ஆராய்ச்சியின் நொநதா தங்களது பெயனரநயா அல்ெது அனடயாளங்கனளநயா 
பவளியிடமாட்நடாம் என்ெனதயும் பதரிவித்துக்பகாள்கிநறாம் 
 .    இந்த ஆராய்ச்சியில் ெங்நகற்ெது தங்களுனடய விருப்ெத்தின்  நெரில் தான் 
இருக்கிறது.நமலும்   ீங்கள் எந்ந ரமும் இந்த ஆராய்ச்சியிெிருந்து 
ெின்வாங்கொம் என்ெனதயும் பதரிவித்துபகாள்கிநறாம். 
    இந்த சிறப்பு ெரிநசாதனைகளின் முடிவுகனள ஆராய்ச்சியின் நொது  அல்ெது 
ஆராய்ச்சியின் முடிவின்  நொது தங்களுக்கு அறிவிப்நொம் என்ெனதயும் 
பதரிவித்துக்பகாள்கிநறாம். 
 
ஆராய்ச்சியாளர் னகபயாப்ெம்            ெங்நகற்ொளர் னகபயாப்ெம் 
நததி : 
 
 
ஆராய்ச்சி ஒப்புதல் கடிதம் 
ஆராய்ச்சி  தனெப்பு: உயர் இரத்த அழுத்தம் உள்ள ந ாயாளிகளுக்கு 
பெப்டின் மரெணுவின் நவறுொடு உள்ளதா என்ெனத கண்டறிதல்  
பெயர் :                              நததி                   : 
வயது :               புற ந ாயாளி எண்       :                        
ொல்  :                              ஆராய்ச்சி நசர்க்னக எண் : 
     இந்த ஆராய்ச்சியின் விவரங்களும் அதன் ந ாக்கங்களும் முழுனமயாக 
எைக்கு பதளிவாக விளக்கப்ெட்டது. 
     எைக்கு விளக்கப்ெட்ட விஷயங்கனள புரிந்து பகாண்டு  ான் எைது 
சம்மதத்னதத் பதரிவிக்கிநறன். 
                   எைக்கு  இரத்த ெரிநசாதனை பசய்து பகாள்ள சம்மதம்.  
      இந்த ஆராய்ச்சியில் ெிறரின்  ிர்ெந்தமின்றி என் பசாந்த 
விருப்ெத்தின் நெரில் தான் ெங்கு பெறுகிநறன் மற்றும்  ான் இந்த 
ஆராய்ச்சியிெிருந்து எந்ந ரமும் ெின்வாங்கொம் என்ெனதயும், அதைால் 
எந்த ொதிப்பும் ஏற்ெடாது என்ெனதயும் புரிந்து பகாண்நடன். 
 
       ான் உயர் இரத்த அழுத்த ந ாயில் பெப்டின் மரெணுவின் 
 நவறுொனட அறிய நமற்பகாள்ளப்ெடும் இந்த  ஆராய்ச்சியின் விெரங்கனளக் 
பகாண்ட தகவல்  தானளப் பெற்றுக் பகாண்நடன். 
 
      இதன் மூெம் எந்த  ெின்வினளவும் வராது எை மருத்துவர் மூெம் 
பதரிந்து பகாண்டு என்னுனடய சுய ினைவுடன் மற்றும் முழு 
சுதந்திரத்துடன் இந்த மருத்துவ ஆராய்ச்சியில் என்னை நசர்த்துக்பகாள்ள 
சம்மதிக்கிநறன் .   
 
                                                 
                                                     னகபயாப்ெம் 
 
 
